carbapenems has been researched along with Bacterial Infections, Gram-Negative in 388 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (1.55) | 18.2507 |
2000's | 54 (13.92) | 29.6817 |
2010's | 202 (52.06) | 24.3611 |
2020's | 126 (32.47) | 2.80 |
Authors | Studies |
---|---|
Czech, M; Holubar, M; Ong'uti, S; Robilotti, E | 1 |
Agarwal, A; Arshad, Z; Gupta, P; Kumari, M; Prakash, V; Siddiqui, SS; Tripathi, P; Venkatesh, V; Verma, S | 1 |
Bassetti, M; Castaldo, N; Giacobbe, DR; Vena, A | 1 |
Jiang, RL; Xia, GL | 1 |
Bassetti, M; Cenderello, G; Falletta, A; Giacobbe, DR; Vena, A | 1 |
Bassetti, M; Giacobbe, DR; Russo, C; Vena, A | 1 |
Tenover, FC | 1 |
Bou, G; Díaz-Regañón, J; Fariñas, MC; Fenoll, R; Ferrer, R; Gómez-Ulloa, D; Lara, N; López, D; Lozano, V; Maseda, E; McCann, E; Salavert, M | 1 |
Russo, A; Torti, C; Trecarichi, EM | 1 |
Chakraborty, DS; Chatterjee, S; Choudhury, S; Lahiry, S | 1 |
Cabebe, AE; Eriguchi, Y; Hawes, C; Ouellette, AJ; Pike, K; Schaal, JB; Selsted, ME; Tran, DQ; Tran, PA; Trinh, K | 1 |
Akova, M; Bassetti, M; Bitterman, R; Bonomo, RA; Carrara, E; Daikos, GL; de Waele, J; Gandra, S; Garnacho-Montero, J; Harbarth, S; Lindemann, PC; Mouton, JW; Paul, M; Pulcini, C; Retamar, P; Rodríguez-Baño, J; Seme, K; Tacconelli, E; Tängdén, T; Tumbarello, M; Yu, Y | 1 |
Bassetti, M; Echols, R; Ferrer, R; Lodise, TP; Naas, T; Niki, Y; Paterson, DL; Zeitlinger, M | 1 |
Alves, EG; da Costa Lamounier, TA; de Araújo, WN; de Castro E Caldo Lima, GR; de Oliveira, PM; Faria-Junior, C; Haddad, R; Pereira, AL | 1 |
Abdissa, S; Bosselmann, M; Feldt, T; Fuchs, A; Häussinger, D; Hurissa, Z; Luedde, T; Mackenzie, CR; Nordmann, T; Orth, HM; Pfeffer, K; Schönfeld, A; Tufa, TB; Wienemann, T | 1 |
Fortaleza, CMCB; Leite, GS; Oliveira, JDS; Pereira, MADM; Sampaio, NCFM | 1 |
Abdul-Aziz, MH; Bassetti, M; de Montmollin, E; Giacobbe, DR; Roberts, JA; Timsit, JF | 1 |
Agakidou, E; Antachopoulos, C; Darda, VM; Iosifidis, E; Kirvasilis, F; Papakonstantinou, E; Roilides, E; Sdougka, M; Simitsopoulou, M; Zarras, C | 1 |
Biswas, NR; Katiyar, A; Kaur, P; Kumar, A; Kumar, B; Kumar, M; Kumari, N; Priya, P | 1 |
Cruz-López, F; Garza-González, E; Maldonado-Garza, HJ; Martínez-Meléndez, A; Morfin-Otero, R; Rodriguez-Noriega, E | 1 |
Albur, M; Barlow, G; Dodgson, AR; Enoch, DA; Gill, K; Goldenberg, SD; Jones, L; Longshaw, C; Lopes, S; Manissero, D; Marek, A; Micallef, C; Parcell, BJ; Wilson, APR | 1 |
Chen, J; Chen, Y; Huang, M; Liang, Q; Xu, Y | 1 |
Feng, S; Wang, H; Zhen, S | 1 |
Bassetti, M; Kanj, SS; Kiratisin, P; Rodrigues, C; van Duin, D; Villegas, MV; Yu, Y | 1 |
Badia, X; Cantón, R; Del Pozo, JL; Ferrer, R; García-Vidal, C; Garnacho-Montero, J; Giró-Perafita, N; Larrosa, N; Pintado, V; Rascado, P; Salavert, M; Soriano, A | 1 |
Betthauser, KD; Hetzler, L; Kollef, MH; Micek, ST; Yuenger, V | 1 |
Cabañero-Navalón, MD; Garcia-Bustos, V; Salavert Lletí, M | 1 |
Maseda, E; Suárez de la Rica, A | 1 |
Clancy, CJ; Nguyen, MH | 1 |
Brink, AJ; Prentice, E; Richards, G; Tootla, H | 1 |
Assanelli, AA; Bernardi, M; Carletti, S; Carrabba, MG; Castagna, A; Ciceri, F; Clerici, D; Corti, C; Erbella, F; Farina, F; Galli, L; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Lugli, AP; Lupo Stanghellini, MT; Mancini, N; Mastaglio, S; Nitti, R; Oltolini, C; Peccatori, J; Poli, A; Ripa, M; Ruggeri, A; Scarpellini, P; Tassan Din, C; Xue, E | 1 |
Li, W; Liu, K; Liu, Y; Sun, J; Xu, H | 1 |
Christaki, E; Cross, ELA; Del Toro, MD; Eckmann, C; Friedrich, AW; Giannella, M; Guirao, X; Kluytmans, J; Mutters, NT; Presterl, E; Righi, E; Sganga, G; Tacconelli, E; Tsioutis, C; Visentin, A | 1 |
Badia, X; Barral, P; Cantón-Bulnes, L; Contreras, S; Del Cerro, I; Ferrer, R; Garnacho-Montero, J; Rascado, P | 1 |
Biehl, LM; Ket, JCF; Remmelzwaal, S; van Dijk, K; Vandenbroucke-Grauls, CMJE; Vehreschild, MJGT; Willems, RPJ | 1 |
Chamilos, G; Ioannou, P; Kofteridis, DP; Kritsotakis, EI; Mathioudaki, A; Petrodaskalaki, M; Spanias, C; Spernovasilis, N; Vouidaski, A | 1 |
Chen, X; Feng, Z; Liao, Q; Lin, H; Lin, J; Zhou, Y; Zhuo, H | 1 |
Bilen, NM; Cilli, F; Güner Özenen, G; Kurugöl, Z; Ozdemir Karadas, N; Ozek, G; Sahbudak Bal, Z; Yazici, P; Yildirim Arslan, S | 1 |
Ardebili, A; Izanloo, A; Rastegar, M | 1 |
König, E; Zollner-Schwetz, I | 1 |
Chen, B; Chen, D; Chen, Y; Guan, X; Hu, B; Hu, F; Huang, X; Li, J; Li, X; Li, Y; Liu, Z; Lv, X; Ni, Y; Qiu, H; Qu, J; Ren, J; Shi, Y; Wang, J; Wang, M; Wu, A; Wu, D; Xia, J; Xu, Y; Yang, F; Yang, Q; Yang, W; Yu, Y; Zeng, M; Zhang, J; Zhou, H; Zhuo, C; Zong, Z | 1 |
Bonomo, RA; Calvopiña, K; Dmitrienko, GI; Hinchliffe, P; Mojica, MF; Rabe, P; Schofield, CJ; Spencer, J; Vila, AJ | 1 |
Carmona, P; Córdoba-Fernández, M; de la Fuente, C; Domínguez, A; García, L; Guzmán-Puche, J; López-Viñau, T; Machuca, I; Martínez-Martínez, L; Merino, N; Robles, JC; Rodríguez, M; Torre-Cisneros, J; Vaquero, JM | 1 |
Antachopoulos, C; Darda, VM; Haidich, AB; Iosifidis, E; Kirvasilis, F; Kontou, A; Papakonstantinou, E; Roilides, E; Sdougka, M; Zarras, C | 1 |
Chen, Y; Hu, Q; Liu, YP; Long, WM; Qu, J; Qu, Q; Wang, Q; Wu, XL; Xiao, YW; Xu, TT; Zhuang, HH | 1 |
Cao, Y; He, LY; Lu, GP; Wang, CQ; Wang, LS; Yin, LJ; Zhai, XW | 1 |
Aiqin, L; Wenwen, S; Xiquan, L | 1 |
Anderson, AJ; Burton, T; Dillon, R; Puzniak, L; Seare, J | 1 |
Shah, BK; Wang, C; Wang, J; Xie, S; Xiong, J; Zhao, J | 1 |
Hu, C; Liu, Y; Lv, X; Qu, J; Xu, J; Zhong, C | 1 |
Chen, WC; Cheng, HY; Hung, CC; Lin, MH; Lin, YC; Shen, YC; Teng, CK | 1 |
Accordini, S; Azzini, AM; Bazaj, A; Be, G; Coledan, I; Lambertenghi, L; Lo Cascio, G; Mazzaferri, F; Miotti, J; Mirandola, M; Naso, L; Salerno, ND; Tacconelli, E | 1 |
Acevedo, J; Araos, R; D'Agata, EMC; Ferreccio, C; González, M; Huidobro, LA; Jara, A; Khan, A; Maureira, L; Munita, JM; Paredes, C; Park, BJ; Peters, A; Rioseco, ML; Rivas, L; Sánchez, F; Sepulveda, D; Smith, RM; Soto, PR; Spencer-Sandino, M; Styczynski, A; Undurraga, E; Usedo, P; Wettig, LR | 1 |
Bezerra, CLPAM; Boszczowski, I; Dias, MBS; Dos Santos, EL; Freire, MP; Levin, AS; Oliveira, MS; Salomão, MC | 1 |
Fang, C; Li, J; Zhou, M; Zhou, Z | 1 |
Bae, S; Cho, K; Han, H; Jung, J; Kim, EO; Kim, J; Kim, SH; Lee, SO; Park, I; Son, HJ | 1 |
Aguado Ventura, C; Alpaca-Salvador, HA; Amaro, C; Astocondor, L; Barco-Yaipén, E; Bocangel Fernandez, C; Briones, A; Burgos, A; Campana, R; Castañeda-Sabogal, A; Castillo, K; Chincha, O; Coaquira, A; Concha-Velasco, F; Cuadros, EC; Díaz Sipión, R; Diaz, JC; Fernandez, V; García, C; Hinostroza, N; Hueda-Zavaleta, M; Ingelbeen, B; Jacobs, J; Krapp, F; López, E; Paricahua Peralta, E; Peralta Córdova, T; Pino-Dueñas, JE; Rondon, CR; Sarmiento Lopez, F; Sierra Chavez, E; Sullón Zavaleta, PA; Valera-Krumdieck, M; Vásquez, R; Vidaurre Torres, AM; Villegas-Chiroque, M | 1 |
Caseris, M; Cohen, R; Dortet, L; Lorrot, M; Raymond, J; Toubiana, J | 1 |
Bartolini, A; Bartoloni, A; Bernardo, M; Bianco, V; Botta, A; Faragona, A; Giacometti, A; Giani, T; Graziani, L; Lagi, F; Morroni, G; Parrella, R; Piccica, M; Rossolini, GM; Spinicci, M; Tavio, M | 1 |
Baum, K; Bonomo, RA; Doi, Y; Evans, SR; Fowler, VG; Hamasaki, T; Komarow, L; Lodise, TP; Patel, R; Rodvold, KA; Rouphael, N; Satlin, MJ; Schwager, N; Souli, M; Tamma, PD; van Duin, D; Van Tyne, D | 1 |
Campos, J; Diaz Högberg, L; Eckmanns, T; Giske, CG; Grundmann, H; Heuer, OE; Jarlier, V; Johnson, AP; Kahlmeter, G; Monen, J; Monnet, DL; Pantosti, A; Rossolini, GM; Simonsen, GS; van de Sande-Bruinsma, N; Vatopoulos, A; Żabicka, D; Žemličková, H | 1 |
Dela Cruz, CM; Shettima, SA; Tenover, FC; Tickler, IA | 1 |
Coppola, N; Di Caprio, G; Onorato, L; Signoriello, S | 1 |
Cotta, MO; Dulhunty, JM; Eriksson, L; Harris, P; Malacova, E; Milinovich, GJ; Vickers, ML | 1 |
Beyene, D; Bitew, A; Evans, M; Fantew, S; Mihret, A | 1 |
Brink, AJ | 1 |
Bouza, E; Burillo, A; Muñoz, P | 1 |
Carroll, KC; Chambers, KK; Goodman, K; Kazmi, AQ; Lewis, S; Milstone, AM; Opene, BNA; Simner, PJ; Tamma, PD; Wang, R; Workneh, M | 1 |
Chen, F; Chen, X; Deng, Y; Han, L; Pang, X; Qian, Y; Shen, C; Xia, Q; Zhang, J; Zhang, Z | 1 |
Baier, C; Bange, FC; Beck, M; Beutel, G; Bollin, R; Ebadi, E; Eder, M; Hintze, SC; Kharazipour, D; Lueck, C; Panagiota, V; Ziesing, S | 1 |
Bell, D; Humphries, R; McKinnell, JA; Miller, L; Needleman, J; Richter, SE; Uslan, DZ; Watson, K | 1 |
Asmara, W; Dwiprahasto, I; Mulyono, B; Sianipar, O | 1 |
Doi, Y | 1 |
Nordmann, P; Poirel, L | 1 |
Pal, A; Tripathi, A | 1 |
Harris, PNA; Henderson, A; Paterson, DL | 1 |
Aguilera-Alonso, D; Baquero-Artigao, F; Cercenado, E; Escosa-García, L; Saavedra-Lozano, J | 1 |
Anastassiou, ED; Assimakopoulos, SF; Christofidou, M; Fligou, F; Karamouzos, V; Kolonitsiou, F; Marangos, M; Papachristou, E; Papadimitriou-Olivgeris, M; Solomou, A; Spiliopoulou, I; Spyropoulou, A; Vamvakopoulou, S | 1 |
Benezit, F; Camus, C; Fillatre, P; Le Tulzo, Y; Massart, N; Moriconi, M | 1 |
Dudeja, S | 1 |
Chang, JS; Chien, HT; Hsieh, KP; Lin, YC; Sheu, CC | 1 |
Abad, CLR; Li, KL | 1 |
Cho, SY; Chung, DR; Ha, YE; Huh, HJ; Huh, K; Kang, CI; Kim, MJ; Kim, SH; Ko, JH; Lee, NY; Peck, KR; Song, JH | 1 |
Calil, FF; de Azevedo Carazatto, PZ; Fortaleza, CMCB | 1 |
Cao, Y; Chen, L; Chen, T; Liu, H; Wang, L; Yang, C; Zhou, W | 1 |
Adam, HJ; Baxter, M; Golden, AR; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 1 |
Gupta, V; McCann, E; Sung, A; Tabak, YP; Vankeepuram, L; Ye, G | 1 |
Andini, R; Antoniadou, A; Bitterman, R; Brill, MJE; Carmeli, Y; Daikos, GL; Daitch, V; Dishon-Benattar, Y; Durante-Mangoni, E; Eliakim-Raz, N; Friberg, LE; Karlsson, MO; Kotsaki, A; Kristoffersson, AN; Leibovici, L; Lellouche, J; Mouton, JW; Nutman, A; Paul, M; Rognås, V; Skiada, A; Theuretzbacher, U | 1 |
Bernardo, M; Bitterman, R; Carmeli, Y; Daikos, G; Daitch, V; Dishon-Benattar, Y; Durante-Mangoni, E; Friberg, LE; Iossa, D; Leibovici, L; Lellouche, J; Mouton, JW; Nutman, A; Paul, M; Skiada, A; Temkin, E; Theuretzbacher, U; Yahav, D; Zusman, O | 1 |
Chen, Y; Jiang, S; Lu, X; Shen, P; Xiao, Y; Yang, P | 2 |
Bosso, JA; Davis, SL; Goff, DA; Rhodes, NJ; Rybak, MJ; Scheetz, MH; Wagner, JL | 1 |
Choe, PG; Hong, JS; Jun, KI; Kang, CK; Kim, I; Kim, NJ; Kim, TS; Koh, Y; Oh, MD; Park, J; Park, S; Park, WB; Shin, DH; Shin, DY; Yoon, SS | 1 |
Adams, ER; Cuevas, LE; Edwards, T; Evans, K; Hobbs, G; Sasaki, S; Sealey, J; Teethaisong, Y; Williams, C | 1 |
Alhmidi, H; Bonomo, RA; Cadnum, JL; Donskey, CJ; Jencson, AL; Koganti, S; Mayer, J; Samore, MH; Wilson, BM | 1 |
Cai, Y; Li, YY; Wang, J; Wang, R | 1 |
Fredricks, DN | 1 |
Aitken, SL; Ajami, NJ; Arias, CA; Galloway-Peña, JR; Kontoyiannis, DP; Sahasrabhojane, PV; Savidge, TC; Shelburne, SA | 1 |
Abbo, L; Claeys, KC; De Pascale, B; Jimenez, A; Martinez, OV; Perez-Cardona, A; Rosello, G; Vega, AD | 1 |
Badia, X; Cantón, R; González, J; Huarte, R; Morata, L; Muñoz, R; Tort, M; Trillo-Mata, JL | 1 |
Cao, X; Chang, H; Chen, S; Chen, Y; Hao, Y; Huang, R; Jia, B; Wu, C; Wu, W; Xiong, Y; Yan, X; Zhang, H; Zhang, Z; Zhou, W | 1 |
Board, MM; Crespo, R; Faux, C; Guard, J; Paul, NC; Shah, DH | 1 |
Breitwieser, FP; Dien-Bard, J; Hao, S; Opene, BNA; Simner, PJ; Tamma, PD; Timp, W; Workman, RE; Yee, R | 1 |
Alves, MZO; Asensi, MD; Bandeira, CS; Beck, DS; Cid, PA; Gomes Junior, SCS; Gomes, MZR; Lima, EM; Lourenço, ND; Marques, JA; Pinheiro, LHZ; Rodrigues, CAS; Santos, RQ; Tonhá, JPS | 1 |
Fasshold, L; Goessler, W; Holl, AM; Kühn, KD; Schmid, M; Steiner, O | 1 |
Harris, P; Isler, B; Kidd, TJ; Paterson, DL; Stewart, AG | 1 |
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
Becker, K; Gysin, M; Haldimann, K; Hobbie, SN; Plattner, M | 1 |
Gikas, A; Karakonstantis, S; Kritsotakis, EI | 1 |
Lai, CC; Tang, HJ; Wang, JH | 1 |
Babiker, A; Clancy, CJ; Clarke, LG; Gealey, JA; Nguyen, MH; Saul, M; Shields, RK | 1 |
Kois, AK; Kuti, JL; Nicolau, DP | 1 |
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
Bakthavatchalam, YD; Dwarakanathan, HT; Nadarajan, A; Soman, R; Veeraraghavan, B; Venkatasubramanian, R | 1 |
Ariyasu, M; Bassetti, M; Doi, Y; Echols, R; Ferrer, R; Lodise, TP; Matsunaga, Y; Naas, T; Nagata, TD; Niki, Y; Paterson, DL; Portsmouth, S; Torre-Cisneros, J; Toyoizumi, K; Wunderink, RG | 1 |
Cai, B; Hsu, WC; Kanakamedala, H; Lodise, TP | 1 |
Giannella, M; Longshaw, C; Lopes, S; Manissero, D; McCool, R; Palacios-Baena, ZR; Rodríguez-Baño, J; Viale, P; Wilson, K | 1 |
Carniel, E; Dias, CG; Narvaez, GA; Perez, LRR | 1 |
Hu, F; Jia, P; Jin, X; Li, M; Qin, X; Tang, YW; Tenover, FC; Wu, S; Yang, Q; Yu, Y; Zhang, H | 1 |
Avendano, EE; Chan, J; McCann, E; Raman, G | 1 |
Bedos, JP; Daikos, G; Dodgson, AR; Ferrer, R; Pan, A; Petrosillo, N; Seifert, H; Vila, J; Wilson, P | 1 |
Bisnauthsing, K; Goldenberg, SD; Merrick, B; Tan, MKI | 1 |
Avcu, G; Cilli, F; Guner Ozenen, G; Kurugol, Z; Ozkinay, F; Sahbudak Bal, Z; Tekin, D; Umit, Z | 1 |
Bechstein, WO; Ferstl, PG; Filmann, N; Heilgenthal, EM; Hogardt, M; Kempf, VAJ; Mücke, MM; Mutlak, H; Schnitzbauer, AA; Schultze, TG; Stephan, C; Trebicka, J; Villinger, D; Waidmann, O; Weiler, N; Welker, MW; Zeuzem, S | 1 |
Feng, C; Li, H; Lv, X; Qu, J | 1 |
Chan, MC; Chen, CM; Feng, JY; Lin, YC; Lin, YT; Peng, CK; Shen, YC; Sheu, CC; Wang, SH; Yang, KY; Zheng, ZR | 1 |
Kyany'a, C; Maybank, R; Musila, L; Oundo, V; Sang, W; Stam, J | 1 |
Babar, ZU; Dodani, SK; Nasim, A | 1 |
Aguirre-Burciaga, E; Alavez-Ramírez, N; Avalos-Aguilera, AM; Aviles-Benitez, LK; Barajas-Magallón, JM; Barlandas-Rendón, NRE; Barrios-Camacho, H; Bello-Pazos, FD; Bobadilla-Del-Valle, M; Bocanegra-Ibarias, P; Bolado-Martínez, E; Cabriales-Zavala, JF; Camacho-Ortiz, A; Canizales-Oviedo, JL; Cetina-Umaña, CM; Choy-Chang, EV; Cobos-Canul, DI; Colin-Castro, CA; Esteban-Kenel, V; Feliciano-Guzmán, JM; Flores-Treviño, S; Fong-Camargo, MG; Franco-Cendejas, R; Galindo-Méndez, M; García-Mendoza, L; García-Romo, R; Garza-González, E; Garza-Ramos, U; Gil-Veloz, M; Guerrero-Núñez, AE; López-García, M; López-Gutiérrez, E; López-Jácome, LE; López-Moreno, LI; Maldonado-Anicacio, JY; Martínez-Villarreal, RT; Mena-Ramírez, JP; Méndez-Sotelo, BJ; Morales-De-la-Peña, CT; Moreno-Méndez, MI; Morfín-Otero, R; Nava-Pacheco, YC; Ortiz-Porcayo, AE; Ostos-Cantú, HL; Perez-Vicelis, T; Ponce-de-León-Garduño, LA; Rojas-Larios, F; Romero-Romero, D; Rosales-García, AA; Santiago-Calderón, MA; Silva-Gamiño, AR; Silva-Sánchez, J; Valero-Guzmán, J; Vázquez-Larios, MDR; Velázquez-Acosta, MDC | 1 |
Bernardi, M; Castagna, A; Castiglion, B; Ciceri, F; Clerici, D; Corti, C; Farina, F; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Mastaglio, S; Oltolini, C; Pavesi, F; Peccatori, J; Ripa, M; Scarpellini, P; Tassan Din, C | 1 |
Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
Altayb, HN; Elbadawi, HS; Elhag, KM; Elton, L; Hamid, MMA; Ippolito, G; Mahgoub, E; McHugh, TD; Ntoumi, F; Osman, AY; Tembo, J; Zumla, A | 1 |
Bragantini, D; Brink, AJ; Carrara, E; Chiamenti, M; Ellis, S; Franceschi, F; Giske, C; Gorska, A; Harris, PNA; Levy-Hara, G; Piddock, LJV; Righi, E; Rohit, A; Savoldi, A; Sharland, M; Tacconelli, E; Tsioutis, C; Zayyad, H | 1 |
Liang, C; Meng, G; Peng, P; Zhang, X; Zhong, L; Zhou, L | 1 |
Bragantini, D; Carrara, E; Chiamenti, M; Ellis, S; Franceschi, F; Piddock, LJV; Righi, E; Savoldi, A; Tacconelli, E | 1 |
Dela Cruz, CM; Dewell, S; Le, VM; Shettima, SA; Sumner, J; Tenover, FC; Tickler, IA | 1 |
Bergman, Y; Carroll, KC; Chambers, KK; Fisher, S; Simner, PJ; Tamma, PD; Yee, R | 1 |
Rhoads, DD | 1 |
Bernard Fourie, P; Osei Sekyere, J; Reta, MA | 1 |
Falagas, ME; Legakis, NJ; Skalidis, T; Vardakas, KZ | 1 |
Brandt, C; Ferstl, PG; Filmann, N; Hogardt, M; Kempf, VAJ; Müller, M; Reinheimer, C; Waidmann, O; Zeuzem, S | 1 |
Wilson, APR | 1 |
Andrews, B; Bifulco, N; Carter, NM; Chen, B; Comita-Prevoir, J; de Jonge, B; Durand-Réville, TF; Ehmann, DE; Gao, N; Giacobbe, RA; Guler, S; Huynh, H; Lahiri, S; McLaughlin, R; McLeod, SM; Miller, AA; Moussa, SH; Mueller, JP; Newman, JV; O'Donnell, J; Olivier, NB; Palmer, T; Shapiro, AB; Thresher, J; Tommasi, RA; Velez-Vega, C | 1 |
Ahmed, MO; Almshawt, N; Elramalli, A | 1 |
Chong, CY; Lim, ASY; Ong, RYL; Seah, VXF; Tan, NWH; Thoon, KC | 1 |
Lee, CH; Liu, JW; Ting, SW | 1 |
Aizawa, Y; Fukuoka, K; Furuichi, M; Higuchi, H; Horikoshi, Y; Ito, K; Kaneko, T; Okazaki, K; Shoji, T; Suwa, J | 1 |
Avcu, G; Aydemir, S; Bekmezci, N; Sahbudak Bal, Z; Sen, S; Soylu, M; Vardar, F | 1 |
Bandettini, R; Cangemi, G; Castagnola, E; Faraci, M; Gattorno, M; Loy, A; Mesini, A; Moscatelli, A | 1 |
Acker, EC; Al-Hasan, MN; Bookstaver, PB; Justo, JA; Kohn, JE | 1 |
Cho, SY; Chung, DR; Ha, YE; Huh, K; Kang, CI; Kim, SH; Lee, NY; Peck, KR; Seok, H; Song, JH | 1 |
Reyes, S; Schuetz, AN; Tamma, PD | 1 |
Akalın, H; Alışkan, HE; Aydın, G; Aydın, M; Azap, A; Azap, Ö; Başaran, S; Bilgin, H; Çakar, ŞE; Can, F; Çavuş, SA; Demir, NA; Demirkaya, H; Demiroğlu, YZ; Erdinç, Ş; Ergen, P; Ergönül, Ö; Hatipoğlu, Ç; Karakoç, Ç; Karaoğlan, I; Kaya, Ş; Keske, Ş; Memikoğlu, O; Menekşe, Ş; Mülazımoğlu, L; Tekin, S; Tezer, Y; Tümtürk, A; Ural, O; Yardımcı, C; Yılmaz, E | 1 |
Aubry, A; Charles-Nelson, A; Compain, F; Dépret, F; Fernandez-Gerlinger, MP; Fournier, A; Katsahian, S; Mainardi, JL | 1 |
Cienfuegos-Gallet, AV; Higuita-Gutiérrez, LF; Jiménez Quiceno, JN; López-López, L; Vargas-Alzate, CA | 1 |
Ayubi, E; Safiri, S | 1 |
Sahbudak Bal, Z | 1 |
Beović, B; Daikos, GL; Durante-Mangoni, E; Kaye, KS; Papst, L; Paul, M; Pulcini, C; Raka, L; Rodríguez-Baño, J | 1 |
Kim, YA; Park, YS | 1 |
Demir, C; Keşli, R | 1 |
Asar, L; Both, A; Katchanov, J; Kluge, S; Klupp, EM; König, C; Maurer, FP; Rohde, H; Rothe, C | 1 |
Britt, NS; Burnham, CD; Durkin, MJ; Hampton, NB; Kollef, MH; Micek, ST; Ritchie, DJ | 1 |
Andini, R; Antoniadou, A; Carmeli, Y; Cavezza, G; Daikos, GL; Dishon Benattar, Y; Durante-Mangoni, E; Eliakim-Raz, N; Leibovici, L; Nutman, A; Paul, M; Pfeffer, I; Skiada, A; Yahav, D; Zak-Doron, Y | 1 |
Antachopoulos, C; Gritsi-Gerogianni, N; Iosifidis, E; Karampatakis, T; Karapanagiotou, A; Karyoti, A; Roilides, E; Tsakris, A; Tsergouli, K | 1 |
Canton, R; Carretto, E; Moore, NM; Traczewski, MM | 1 |
Cheng, C; Li, S; Lu, W; Rui, Y; Sun, J; Yang, Q | 1 |
Cui, M; Gao, Y; Gu, ZC; Zhang, C; Zhang, ZL; Zhao, XY; Zhong, H | 1 |
Jain, A; Parr, TR; Pucci, MJ; Utley, L; Zabawa, T | 1 |
Adjemian, J; Danner, RL; Dekker, JP; Fridkin, S; Hooper, DC; Kadri, SS; Klompas, M; Lai, YL; Palmore, TN; Powers, JH; Prevots, DR; Rhee, C; Ricotta, E; Spaulding, AB; Suffredini, AF | 1 |
Fan, W; Nathanson, BH; Shorr, AF; Sulham, K; Zilberberg, MD | 2 |
Bassetti, M; Giamarellos-Bourboulis, EJ; Graziano, E; Kotsaki, A; Righi, E; Routsi, C | 1 |
Armin, S; Azimi, L; Fallah, F; Ghazvini, K; Hasanzadeh, S; Karimi, A; Samadi Kafil, H | 1 |
Huang, YC; Lin, YT; Wang, FD; Wu, PF | 1 |
Hwang, H; Kim, B | 1 |
Fujita, J; Hishinuma, T; Kirikae, T; Nakama, M; Nakasone, I; Sawachi, Y; Tada, T; Takaesu, R; Uechi, K | 1 |
Alvares, PA; Arnoni, MV; da Silva, CB; Mimica, MJ; Sáfadi, MAP | 1 |
Abrar, S; Ain, NU; Bukhari, SS; Haider, MH; Hussain, S; Iftikhar, A; Rasheed, F; Riaz, S | 1 |
Bădițoiu, L; Bagiu, IC; Coșniță, DA; Dugăeşescu, D; Dumitrașcu, V; Horhat, DI; Horhat, FG; Krasta, A; Licker, M; Muntean, D | 1 |
Gupta, V; McCann, E; Sung, AH; Tabak, YP; Vankeepuram, L; Ye, G | 1 |
Naber, KG; Wagenlehner, FME | 1 |
Adam, MA; Elhag, WI | 1 |
Galani, I; Giamarellou, H; Karaiskos, I; Souli, M | 1 |
Del Giacomo, P; Losito, AR; Tumbarello, M | 1 |
Berberian, G; Brizuela, M; Castro, G; Fiorili, G; Mastroiani, A; Reijtman, V; Rosanova, MT; Santa Cruz, D; Travaglianti, M | 1 |
Adam, HJ; Domalaon, R; Golden, AR; Idowu, T; Karlowsky, JA; Lagacé-Wiens, PRS; Lawrence, CK; Lynch Iii, JP; Noreddin, A; Schweizer, F; Walkty, AJ; Wiebe, K; Zelenitsky, S; Zhanel, GG; Zhanel, MA | 1 |
Alharbi, A; Alshehri, S; Eljaaly, K; Ortwine, JK; Pogue, JM | 1 |
Benzerara, Y; Compain, F; Constant, AL; Gallah, S; Garnier, M; Guerot, E; Labbe, V; Mainardi, JL; Montil, M; Quesnel, C; Siami, S; Vimont, S | 1 |
Hsu, AJ; Tamma, PD | 2 |
Venter, H | 1 |
Demord, A; Mueller, L; Nordmann, P; Ottiger, C; Poirel, L | 1 |
Abdallah, M; Alharthy, A; Alzaagi, I; Badawi, M; Issa, KN; Rasheed, A | 1 |
Andrade, RM; Bozza, FA; Dalmas, B; Dantas, LF; Hamacher, S | 1 |
Bhagwati, G; Bhakuni, P; Chakrabarti, A; Chakrabarti, S; Jaiswal, SR; Joy, A | 1 |
Codjoe, FS; Donkor, ES; Miller, K; Smith, TJ | 1 |
Antachopoulos, C; Iosifidis, E; Karampatakis, T; Karyoti, A; Mouloudi, E; Roilides, E; Tsakris, A; Tsergouli, K | 1 |
Dortet, L; Emeraud, C; Fournier, D; Naas, T; Plésiat, P; Potron, A; Triponney, P | 1 |
Azougagh, K; Barbier, F; Boulain, T; Boutrot, M; Guinard, J | 1 |
Leibovici, L; Paul, M; Zusman, O | 1 |
Apisarnthanarak, A; Hsu, LY; Khawcharoenporn, T; Mundy, LM | 1 |
Falagas, ME; Kapaskelis, A; Tansarli, GS; Vardakas, KZ | 1 |
Bell, JM; Gillespie, EE; Korman, TM; Kotsanas, D; Li, HY; Snook, K; Stuart, RL; Wijesooriya, WR; Williams, N; Wright, L | 1 |
Chang, FY; Chen, RJ; Chen, YH; Chen, YS; Hsueh, PR; Jean, SS; Ko, WC; Lam, C; Lee, WS; Liao, CH; Liu, CY; Liu, JW; Lu, MC; Wu, JJ; Yu, KW | 1 |
Hiramatsu, K; Kikuchi, K; Matsuda, M; Notake, S; Tamai, K; Yanagisawa, H | 1 |
Nanas, S; Papas, V; Pitsiolis, T; Platsouka, E; Pratikaki, M; Roussos, C; Routsi, C; Sotiropoulou, C; Tsakris, A | 1 |
Kemper, AL; Young, DC; Zobell, JT | 1 |
Bracco, S; Brigante, G; Corbo, N; Luzzaro, F; Micheletti, P; Migliavacca, R; Nucleo, E; Piazza, A; Pini, B | 1 |
Grover, N; Khajuria, A; Kumar, M; Praharaj, AK | 1 |
Balkhy, HH; Paterson, DL; Walsh, TR; Zowawi, HM | 1 |
Gardner, J; Toledo-Pereyra, LH; Zaffiri, L | 1 |
Baserni, MN; Jugo, MB; Villar, HE | 1 |
Kanafani, ZA; Kanj, SS; Kmeid, JG; Youssef, MM | 1 |
Bulitta, JB; Landersdorfer, CB; Zavascki, AP | 1 |
Chlebicki, MP; Kwa, AL; Lee, AL; Lee, W; Liew, LT; Lim, CL; Nah, SC; Wan, CN | 1 |
Changawala, N; Chapnick, E; Crusio, R; Kupfer, Y; Paul, V; Rao, S; Tiu, C; van Ginkel, J | 1 |
Apisarnthanarak, A; Bhooanusas, N; Mundy, LM; Yaprasert, A | 1 |
Chiang, MC; Chu, SM; Fu, RH; Hsu, JF; Huang, HR; Huang, YC; Lee, CW; Lien, R; Tsai, MH | 1 |
Chong, YP; Choo, EJ; Chung, JW; Jeon, MH; Kim, DM; Kim, T; Kim, YS; Lee, HK; Moon, C; Park, SY; Peck, KR | 1 |
Ogbolu, DO; Webber, MA | 1 |
Aleksandrova, IV; Borisova, LA; Chernen'kaia, TV; Kosolapov, DA; Nikitina, OV; Reĭ, SI | 1 |
Doumith, M; Hill, R; Hopkins, KL; Jain, A; Livermore, DM; Loy, R; Meunier, D; Pike, R; Turton, J; Woodford, N | 1 |
Carmeli, Y; Durante-Mangoni, E; Leibovici, L; Mouton, JW; Mussini, C; Paul, M; Tacconelli, E; Theuretzbacher, U | 1 |
Badal, RE; Biedenbach, DJ; Bouchillon, SK; Hackel, M; Hoban, DJ; Nga, TT; Phuong, DM; Phuong, NT; Phuong, TT | 1 |
Blanco, VM; Correa, A; Hernández-Gómez, C; Motoa, G; Vallejo, M; Villegas, MV | 1 |
Caio, C; Cormaci, R; Denaro, C; Gennaro, M; Gona, F; Mezzatesta, ML; Quattrone, C; Salerno, I; Stefani, S; Zingali, T | 1 |
Ageevets, VA; Ilina, EN; Lisitsyna, ES; Lobzin, YV; Partina, IV; Shlyapnikov, SA; Sidorenko, SV | 1 |
Bonne, SL; Christopher, KB; Danner, RL; Hohmann, SF; Hooper, DC; Kadri, SS; Moffa, MA; Orav, EJ; Palmore, T; Strich, JR; Timpone, JG; Varughese, C | 1 |
Ali, S; Baqi, S; Kalam, K; Kumar, S; Qamar, F | 1 |
Adachi, J; Bonomo, RA; Perez, F | 1 |
Kaye, KS; Lephart, P; Mynatt, RP; Neelakanta, A; Pogue, JM; Sharma, S | 1 |
Behnke, M; Gastmeier, P; Geffers, C; Maechler, F; Peña Diaz, LA; Schröder, C | 1 |
Li, J; Mukhopadhyay, A; Tambyah, PA; Vasudevan, A; Yuen, EG | 1 |
Cheng, C; Rui, Y; Sun, J; Zheng, F | 1 |
Ang, B; Lew, EL; Lew, KY; Ling, LM; Lye, D; Ng, TM; Tan, M; Tan, SH; Teng, CB | 1 |
Charlett, A; Donaldson, H; Freeman, R; Holmes, AH; Moore, LS | 1 |
Barreto, JN; Tosh, PK; Vasoo, S | 1 |
Kamran, R; Nahid, F; Qamar, MU; Walsh, TR; Zahra, R | 1 |
Bootsma, HJ; Schouls, LM | 1 |
Carmeli, Y; Costa, AN; Grossi, PA; Ippolito, G; Ison, MG; Lanini, S; Procaccio, F; Puro, V; Ricci, A; Vesconi, S; Vespasiano, F | 1 |
Bass, SN; Bauer, SR; Lam, SW; Neuner, EA | 1 |
Bertani, A; Campanella, M; Conaldi, P; Gona, F; Gridelli, B; Grossi, P; Gruttadauria, S; Luca, A; Mularoni, A; Spada, M; Vitulo, P; Vizzini, G | 1 |
Bozdogan, B; Gothandam, KM; Manohar, P; Maray, S; Nachimuthu, R; Sivamangala, K; Subramani, R | 1 |
Andria, N; Domchenko, A; Fraser, D; Henig, O; Kotler, O; Ofran, Y; Oren, I; Paul, M; Zuckerman, T | 1 |
Giannella, M; Lewis, R; Tedeschi, S; Viale, P | 1 |
Denkel, LA; Gastmeier, P; Layer, F; Leistner, R; Pfeifer, Y; Werner, G | 1 |
Boyle, DP; Zembower, TR | 1 |
Abd Rahman, AN; Abdul-Aziz, MH; Lipman, J; Mat-Nor, MB; Roberts, JA; Staatz, CE; Sulaiman, H; Wallis, SC | 1 |
Kaye, KS; Pogue, JM | 1 |
Bass, SN; Bauer, SR; Gibson, GA; Lam, SW; Neuner, EA | 1 |
Altinkanat Gelmez, G; Bakir, M; Karaaslan, A; Kepenekli Kadayifci, E; Söyletir, G; Soysal, A | 1 |
Shah, PG; Shah, SR | 1 |
Rodrigues, C; Shetty, A; Soman, R | 1 |
Huang, ZG; Xu, A; Xu, YC; Zheng, B; Zhong, NS; Zhuo, C | 1 |
Lee, JY; Lertharakul, T; Miglis, CM; O'Donnell, JN; Scheetz, MH; Tuvell, M | 1 |
Anuj, SN; Bergh, H; George, NM; Heney, C; Nimmo, GR; Paterson, DL; Sidjabat, HE; Sinclair, HA | 1 |
Mustapha, A; Pfeifer, Y; Singh, P | 1 |
Chukwuma, U; Clifford, R; Gierhart, S; Hinkle, M; Lesho, E; Neumann, C; Richesson, D; Sparks, M; Waterman, P | 1 |
Carroll, KC; Martin, I; Milstone, AM; Opene, B; Simner, PJ; Tamma, PD | 1 |
Fransén, J; Hanberger, H; Huss, FR; Nilsson, LE; Rydell, U; Sjöberg, F | 1 |
Bastos, AN; Bastos, LQ; Bastos, VQ; Da Silva, VL; Dias, VC; Diniz, CG; Peter, AC | 1 |
Al-Masaudi, S; Elawady, S; Elsherif, R; Harakeh, S; Ismail, D; Jastaniah, S; Karrouf, G | 1 |
Clarkson, L; Hanberger, H; Hf, W; Hoang, BTN; Khu, DTK; Lam, YM; Larsson, M; Le, HT; Le, NK; Nadjm, B; Nguyen, KV; Nguyen, TH; Nilsson, LE; Rydell, U; Thai, TQ; Vo, VT; Vu, DTV; Vu, PD | 1 |
El Salabi, AA; Elahmer, O; Ghenghesh, KS; Kraiem, AG; Zorgani, A | 1 |
Wilson, AP | 1 |
Mayor, S | 1 |
Bartoletti, M; Cavina, A; Cristini, F; Giannella, M; Liverani, A; Pederzini, R; Pignanelli, S; Tedeschi, S; Toni, L; Trapani, F; Tumietto, F; Viale, P | 1 |
Altunin, S; Benattar, YD; Daitch, V; Elbaz, M; Granot, M; Leibovici, L; Omar, M; Paul, M; Yahav, D; Zak-Doron, Y; Zusman, O | 1 |
Harris, PN; Lane, SW; Liborio, M; Paterson, DL; Peri, AM; Righi, E; Wailan, AM | 1 |
Aykac, K; Basaranoglu, ST; Cengiz, AB; Ceyhan, M; Kara, A; Karahan, S; Ozsurekci, Y; Sancak, B | 1 |
Ebara, H; Hagiya, H; Haruki, Y; Kondo, E; Otsuka, F | 1 |
Adil, S; Habib, F; Hasan, R; Idrees, F; Irfan, S; Mehraj, V | 1 |
Friedland, I; Jasovich, A; Jiang, J; Kaniga, K; Lucasti, C; Umeh, O | 1 |
Brown, NP; Pillar, CM; Sahm, DF; Shah, D; Torres, MK | 1 |
Basso, M; Costa, SF; Gobara, S; Gomez, LB; Levin, AS; Oshiro, I; Paez, JG; Spadão, F | 1 |
Haldorsen, B; Lundblad, EW; Samuelsen, O; Simonsen, GS; Sundsfjord, A | 1 |
Castanheira, M; Jones, RN; Livermore, DM | 1 |
Bell, JM; Jones, RN; Sader, HS; Stilwell, MG; Turnidge, JD | 1 |
Dedhia, HV; McKnight, R | 1 |
Rahal, JJ | 2 |
Giamarellou, H; Poulakou, G | 2 |
Overturf, GD | 1 |
Devasahayam, G; Hoffman, PS; Scheld, WM | 1 |
Cornaglia, G; Rossolini, GM | 1 |
Akova, M; Carmeli, Y; Cornaglia, G; Daikos, GL; Garau, J; Giamarellou, H; Harbarth, S; Rossolini, GM; Souli, M | 1 |
Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC | 1 |
Aldous, WK; Co, EM | 1 |
Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
Flamm, R; Kaniga, K; Nandy, P; Samtani, MN | 1 |
Amsler, K; Bush, K; Flamm, R; Foleno, B; Santoro, C | 1 |
Lumb, J | 1 |
Cohen, R; Durrmeyer, X | 1 |
Cassettari, M; Chongthaleong, A; Christiansen, KJ; Cooper, D; Flamm, R; Garcia, J; Hsu, L; Ip, M; Ker, HB; Kiratisin, P; Mendoza, M; Morrissey, I; Okolo, P; Quintana, A; Redjeki, IS | 1 |
Ko, KS; Lee, H; Peck, KR; Song, JH | 1 |
Armand-Lefevre, L; Drugeon, HB; Gjoklaj, M; Kitzis, MD; Lascols, C; Leclercq, R; Legrand, P; Lemire, A; Mérens, A; Miara, A; Moubareck, C; Muller-Serieys, C; Reverdy, ME; Roussel-Delvallez, M; Soussy, CJ | 1 |
Nordmann, P | 1 |
Kuijper, EJ; van Dissel, JT | 1 |
Walsh, TR | 1 |
Gomersall, C; Kuti, JL; Kwa, A; Montakantikul, P; Nicolau, DP; Roberts, JA | 1 |
Goulenok, TM; Majed, K; Monchi, M | 1 |
Hassan, A; Kaleem, F; Khan, A; Usman, J | 1 |
Garg, A; Vashishtha, VM | 1 |
Flamm, RK; Korten, V; Laeuffer, JM; Morrissey, I; Mutters, R; Nordmann, P; Picazo, JJ; Quintana, A; Seak, JC | 1 |
Bassetti, M; Ginocchio, F; Mikulska, M | 1 |
Apisarnthanarak, A; Apisarnthanarak, P; Kiratisin, P; Mundy, LM | 1 |
Gray, JW; Patel, M | 1 |
Akalın, H; Akova, M; Arman, D; Aygen, B; Başaran, S; Bayramoğlu, G; Dizbay, M; Dokuzoğuz, B; Eraksoy, H; Esener, H; Hasçelik, G; Köksal, I; Korten, V; Oğünç, D; Sınırtaş, M; Söyletir, G; Sümerkan, B; Tünger, A; Ulusoy, S; Yalçın, AN | 1 |
Beloborodov, VB; Gruver, KP; Kuz'menko, TN | 1 |
Bassetti, M; Giacobbe, DR; Ginocchio, F; Mikulska, M; Taramasso, L | 1 |
Balderson, BJ; Patil, NP; Suda, KJ; Yates, ME | 1 |
Livermore, DM; Nordmann, P; Poirel, L; Walsh, TR | 1 |
Bharadwaj, R; Dohe, V; Gaikwad, V; Joshi, S; Kulkarni, G; Shouche, Y | 1 |
Farbman, L; Leibovici, L; Paul, M; Yahav, D | 1 |
Abandeh, FI; Drew, ME; Sopirala, MM | 1 |
Badal, RE; Boffard, KD; Botha, RF; Brink, AJ; Feldman, C; Grolman, DC; Joubert, I; Poswa, X; Pretorius, J; Richards, GA; Senekal, M; Veller, M | 1 |
Bille, E; Carbonnelle, E; Cattoir, V; Corvec, S; Fihman, V; Illiaquer, M; Jacquier, H; Jaureguy, F; Le Monnier, A; Tankovic, J; Zahar, JR | 2 |
Borra, PS; El Salabi, A; Samuelsen, Ø; Toleman, MA; Walsh, TR | 1 |
Baris, H; Cakir, N; Celen, M; Kurt, H; Laeuffer, J; Leblebicioglu, H | 1 |
Babu, E; Bäcker, M; Bratu, S; Kelly, P; Landman, D; Olawole, O; Quale, J; Shah, N | 1 |
Chongthaleong, A; Davies, T; Garcia, J; Kiratisin, P; Lagamayo, E; Roberts, S; Tan, TY | 1 |
Boyd, DA; Bryce, E; Embree, J; Gravel, D; Katz, K; Kibsey, P; Kuhn, M; Mataseje, LF; Mounchili, A; Mulvey, MR; Roscoe, D; Simor, A; Taylor, G; Thomas, E; Turgeon, N | 1 |
Cleveland, KO; Gelfand, MS | 1 |
Akova, M; Carmeli, Y; Daikos, GL; Tzouvelekis, L | 1 |
Han, L; He, X; Huang, L; Li, X; Liu, D; Liu, F; Liu, W; Shao, C; Wang, J; Wang, S; Wang, X; Wang, Y; Wei, X; Yang, Z; Yin, Z; Yuan, J; Zhu, L; Zou, D | 1 |
Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
Esterly, JS; McLaughlin, MM; Postelnick, MJ; Qi, C; Scheetz, MH; Wagner, J | 1 |
Dahle, UR; Samuelsen, Ø; Sundsfjord, A; Wester, AL | 1 |
Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Kositpantawong, N; Wongpoowarak, W | 1 |
Amoureux, L; Bador, J; Blanc, E; Neuwirth, C | 1 |
Keel, RA; Kiratisin, P; Nicolau, DP | 1 |
Blackburn, J; Bourgault, AM; Domingo, MC; Gilbert, A; Grenier, S; Lavergne, V; Lefebvre, B; Pilotte, J; Tremblay, C; Tsimiklis, C | 1 |
Eguchi, K; Eriguchi, Y; Fujimoto, K; Hatano, K; Kanazawa, K; Matsumoto, M; Nakai, T; Sato, K; Shimizudani, T; Sunagawa, M; Takemoto, K; Terashita, S; Ueda, Y | 1 |
Rajdev, S; Shivaprakasha, S; Singh, H; Velivala, S | 1 |
Daikos, G; Katerelos, P; Kontopidou, F; Maltezou, HC; Roilides, E; Theodoridou, M | 1 |
Johnson, AP; Woodford, N | 1 |
Patterson, JE | 2 |
Akiyama, K; Hiramatsu, N; Igari, J; Koyama, T; Oguri, T | 1 |
Héritier, C; Nordmann, P; Poirel, L | 1 |
Huang, ST; Ko, WC; Lee, HC; Lee, NY; Liu, KH; Yan, JJ | 1 |
Abe, T; Fukuoka, T; Hirota, T; Inoue, H; Kakuta, M; Kitayama, A; Koga, T; Kuwahara, S; Masuda, N; Matsushita, Y; Nakagawa, M; Ohya, S; Shibayama, T; Sugihara, C; Takenouchi, T; Utsui, Y; Yoshida, T | 1 |
Brahmadathan, KN; Gladstone, P; Rajendran, P | 1 |
Avlamis, A; Katsandri, A; Legakis, NJ; Pantazatou, A; Papaparaskevas, J | 1 |
Kizirgil, A; Toraman, ZA; Yakupogullari, Y | 1 |
Eguchi, K; Eriguchi, Y; Kanazawa, K; Sunagawa, M; Takemoto, K; Ueda, Y | 1 |
Rossolini, GM | 1 |
Bell, JM; Franklin, C; Peleg, AY; Spelman, DW | 1 |
Chen, WH; Hsueh, PR; Luh, KT | 1 |
Chayakulkeeree, M; Junsriwong, P; Keerasuntonpong, A; Thamlikitkul, V; Tribuddharat, C | 1 |
Eta, S; Kawahara, M | 1 |
Iredell, JR; Sintchenko, V | 1 |
Paterson, DL | 1 |
Benjamin, DK; Cotten, CM; Goldberg, RN; McDonald, S; Poole, K; Stoll, B | 1 |
Franklin, C; Liolios, L; Peleg, AY | 1 |
Daschner, FD; Gastmeier, P; Jonas, D; Meyer, E; Rueden, H; Schwab, F | 1 |
Bernander, S; Ericson, E; Fraenkel, CJ; Larsson, P; Melhus, A; Rydberg, J; Törnqvist, E; Ullberg, M | 1 |
Archontoulis, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Mega, A; Pavleas, I; Rigas, K; Thomopoulos, G; Vernikos, P | 1 |
Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
Fraser, VJ; Fridkin, SK; Kollef, MH; Merz, LR; Warren, DK | 1 |
Aisenberg, G; Dickey, BF; Kontoyiannis, DP; Raad, II; Rolston, KV; Safdar, A | 1 |
Espedido, B; Iredell, J; Thomas, L | 1 |
Araujo, VR; Carvalho-Dias, VM; Cunha, CA; de Souza, CA; de Souza, M; Godoy, C; Lotfi, CJ; Maiolino, A; Nucci, M; Oliveira, AL; Pasquini, R; Ruiz, MA; Seber, A; Silla, L; Simões, BP; Tanaka, PY; Trabasso, P; Urakawa, P; Zanichelli, MA | 1 |
Coratza, G; Docquier, JD; Mantengoli, E; Musmanno, RA; Rossolini, GM | 1 |
Abraham, OC; Brahmadathan, KN; Jagannati, M; John, G; Kaul, S; Pitchamuthu, K; Sudarsanam, TD | 1 |
Nordmann, P; Pitout, JD; Poirel, L | 1 |
Cherkashin, EA; Galeeva, EV; Ivanov, DV; Krapivina, IV; Sidorenko, SV; Veshutova, NS | 1 |
Deptuła, A; Gierlotka, K; Gospodarek, E; Michalska, A | 1 |
Shah, PM | 1 |
Kuti, JL; Nicasio, AM; Nicolau, DP | 1 |
Jayashree, M; Mathew, JL; Ray, P; Singhi, S | 1 |
Falagas, ME; Vergidis, PI | 1 |
Ramphal, R | 1 |
Owens, RC | 1 |
Arakawa, Y; Ichiyama, S; Ito, H; Kato, N; Nakashima, K; Ohsuka, S; Ohta, M; Senda, K; Shimokata, K | 1 |
Domon, H; Furuya, N; Ishii, K; Matsumoto, T; Miyazaki, S; Ohno, A; Tateda, K; Yamaguchi, K | 1 |
Mokaddas, EM; Sanyal, SC | 1 |
Kuwabara, K; Wada, K | 1 |
Biedenbach, DJ; Jones, RN; Kugler, KC | 1 |
Allerberger, F; Reisinger, EC | 1 |
Iwatsubo, E; Kawakami, Y; Manabe, N; Matsumoto, T; Takahashi, K | 1 |
Forward, KR; Gales, AC; Jones, RN; Liñares, J; Sader, HS; Verhoef, J | 1 |
Dascal, A; Miller, MA; Zaharatos, GJ | 1 |
Akova, M; Gür, D; Kocagöz, S; Köseoğlu , O | 1 |
104 review(s) available for carbapenems and Bacterial Infections, Gram-Negative
Article | Year |
---|---|
Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2022 |
Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Sepsis | 2021 |
Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Polymyxins | 2022 |
New antibiotics for the treatment of nonfermenting Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2021 |
The role of Gram-negative bacteria in skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Soft Tissue Infections | 2022 |
Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Topics: Adult; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefiderocol; Cephalosporins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Siderophores; Urinary Tract Infections | 2022 |
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Critical Care; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2022 |
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Prospective Studies | 2022 |
Efficacy and
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Tazobactam | 2022 |
Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Drug Combinations; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2022 |
A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Consensus; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pneumonia; Respiratory System; Risk Factors | 2022 |
New antimicrobial treatment options for severe Gram-negative infections.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2022 |
Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cattle; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Microbial Sensitivity Tests; Quinolones; Tetracyclines | 2022 |
The role of cefiderocol in clinical practice.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests | 2022 |
Epidemiology of Gram-negative bacteria during coronavirus disease 2019. What is the real pandemic?
Topics: Anti-Bacterial Agents; Carbapenems; COVID-19; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pandemics | 2022 |
ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Monobactams; Prospective Studies | 2023 |
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Regression Analysis; Vancomycin-Resistant Enterococci | 2023 |
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Polymyxin B; Polymyxins; Retrospective Studies; Rifampin | 2023 |
Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacterial Infections; Humans; Imipenem; Urinary Tract Infections | 2023 |
Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infection Control | 2023 |
Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Intraabdominal Infections; Network Meta-Analysis; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2023 |
Treatment of Resistant Gram-negative bacilli in children.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2023 |
Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2019 |
Modifiable risk factors for multidrug-resistant Gram-negative infection in critically ill burn patients: a systematic review and meta-analysis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Burns; Carbapenems; Cephalosporins; Critical Illness; Cross Infection; Drug Resistance, Multiple; Gram-Negative Bacterial Infections; Humans; Hydrotherapy; Intensive Care Units; Penicillins; Respiration, Artificial; Risk Factors; Urinary Catheters; Vascular Access Devices | 2019 |
Epidemiology of carbapenem-resistant Gram-negative infections globally.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactam Resistance; Carbapenems; Global Health; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Prevalence; Public Health Surveillance | 2019 |
Risk stratification for multidrug-resistant Gram-negative infections in ICU patients.
Topics: beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Cross Infection; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Mass Screening; Prognosis; Risk Assessment; Risk Factors | 2019 |
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Clinical Trials as Topic; Drug Resistance, Bacterial; Forecasting; Gram-Negative Bacterial Infections; Humans; Public Health | 2019 |
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.
Topics: Carbapenems; Drug Resistance, Bacterial; Global Health; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2019 |
Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftriaxone; Cephalosporin Resistance; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Randomized Controlled Trials as Topic | 2020 |
Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans | 2020 |
Neonatal Sepsis: Treatment of Neonatal Sepsis in Multidrug-Resistant (MDR) Infections: Part 2.
Topics: Anti-Bacterial Agents; beta-Lactamases; Blood Culture; Carbapenems; Colistin; Drug Resistance, Multiple; Enterobacteriaceae; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; India; Klebsiella; Neonatal Sepsis | 2020 |
Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Carbapenems; Cohort Studies; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Renal Replacement Therapy | 2020 |
Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Treatment Outcome | 2020 |
Topics: Achromobacter; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Klebsiella Infections; Klebsiella pneumoniae; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Tigecycline | 2020 |
Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Genotyping Techniques; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2020 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Is it time to move away from polymyxins?: evidence and alternatives.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Developing Countries; Drug Resistance, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Polymyxins | 2021 |
Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review.
Topics: Carbapenems; Case-Control Studies; Cross Infection; Dialysis; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Length of Stay; Prospective Studies; Respiration, Artificial; Retrospective Studies; Risk Factors | 2021 |
Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis.
Topics: Aged; Carbapenems; Cost of Illness; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Length of Stay; Male; Middle Aged | 2020 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Clinical Studies as Topic; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pseudomonas aeruginosa | 2021 |
Risk factors for, and molecular epidemiology and clinical outcomes of, carbapenem- and polymyxin-resistant Gram-negative bacterial infections in pregnant women, infants, and toddlers: a systematic review and meta-analyses.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbapenems; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Middle Aged; Molecular Epidemiology; Mortality; Polymyxins; Pregnancy; Pregnancy Complications, Infectious; Risk Assessment; Risk Factors; Young Adult | 2021 |
Sparing carbapenem usage.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Utilization; Formularies, Hospital as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2017 |
Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Carbapenems; Clinical Decision-Making; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination | 2018 |
Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea.
Topics: Acinetobacter baumannii; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Republic of Korea; Retrospective Studies | 2018 |
Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Colistin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Patient Safety; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Urinary Tract Infections | 2018 |
Tebipenem, the first oral carbapenem antibiotic.
Topics: Administration, Oral; Adult; Animals; Anti-Bacterial Agents; Carbapenems; Drug Design; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Prodrugs | 2018 |
Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2019 |
The role of carbapenem-resistant pathogens in cSSTI and how to manage them.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Diagnostic Tests, Routine; Disease Management; Drug Therapy; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Skin Diseases, Bacterial; Soft Tissue Infections | 2019 |
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Molecular Structure; Randomized Controlled Trials as Topic; Siderophores | 2019 |
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials as Topic; Colistin; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Randomized Controlled Trials as Topic; Sisomicin; United States; United States Food and Drug Administration; Urinary Tract Infections | 2019 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Reversing resistance to counter antimicrobial resistance in the World Health Organisation's critical priority of most dangerous pathogens.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Drug Discovery; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Permeability; World Health Organization | 2019 |
Meta-analysis of Polymyxin Use in Patients.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Polymyxins; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pseudomonas aeruginosa | 2013 |
β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Middle East; Public Health Surveillance | 2013 |
Combination therapy for Gram-negative bacteria: what is the evidence?
Topics: Anti-Bacterial Agents; Carbapenems; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Minocycline; Polymyxins; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2013 |
Combination therapy for carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Administration Schedule; Drug Dosage Calculations; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Minocycline; Polymyxins; Tigecycline | 2013 |
Treatment of multidrug-resistant Gram-negative infections in children.
Topics: Acinetobacter baumannii; Adult; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Child; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2014 |
Combination therapy for carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Antibiotic-resistant gram-negative bacterial infections in patients with cancer.
Topics: Acinetobacter baumannii; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Neoplasms; Pseudomonas aeruginosa; Stenotrophomonas maltophilia | 2014 |
Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Global Health; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Infection Control | 2015 |
Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans | 2015 |
Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Pseudomonas aeruginosa; Risk Factors | 2015 |
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Infection Control; Microbial Sensitivity Tests; Risk Factors; United States | 2015 |
Carbapenem susceptibility breakpoints, clinical implications with the moving target.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2016 |
Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis.
Topics: Acinetobacter; Adult; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Drug Resistance, Bacterial; Female; Global Health; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Israel; Italy; Klebsiella; Klebsiella Infections; Male; Middle Aged; Neutropenia; Prevalence; Pseudomonas | 2017 |
[Broad-spectrum beta-lactamases in Gram-negative bacteria].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Monobactams; Penicillins; Plasmids | 2008 |
Doripenem: position in clinical practice.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Cross Infection; Doripenem; Drug Interactions; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas Infections | 2009 |
Multidrug-resistant Gram-negative infections: what are the treatment options?
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Minocycline; Polymyxins; Tigecycline | 2009 |
Carbapenemases: a brief review for pediatric infectious disease specialists.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2010 |
Newer antibacterial drugs for a new century.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Drug Delivery Systems; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Drugs, Investigational; Glycopeptides; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Macrolides; Minocycline; Oxazolidinones; Tigecycline | 2010 |
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Health Policy; Humans; Infection Control | 2010 |
[Pediatric use of carbapenems].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Child; Drug Tolerance; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Thienamycins | 2010 |
In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; France; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitals, Teaching; Humans; Microbial Sensitivity Tests | 2011 |
[Gram-negative bacteriae with resistance to carbapenems].
Topics: beta-Lactamases; Carbapenems; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Global Health; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Oxacillin | 2010 |
[The rise of resistant gram-negative bacteria].
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Food Chain; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Veterinary Medicine | 2010 |
Emerging carbapenemases: a global perspective.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Drug Utilization; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Prevalence | 2010 |
Role and impact of carbapenem in nosocomial infections.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Cross Infection; Dosage Forms; Drug Resistance, Microbial; Gram-Negative Bacterial Infections; Humans; Patents as Topic | 2011 |
New treatment options against gram-negative organisms.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cephalosporins; Drug Resistance, Multiple; Drugs, Investigational; Gram-Negative Bacterial Infections; Humans; United States | 2011 |
Management of antibiotic-resistant infection in the newborn.
Topics: Acetamides; Anti-Bacterial Agents; Carbapenems; Colistin; Daptomycin; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Linezolid; Oxazolidinones; Vancomycin | 2011 |
Will new antimicrobials overcome resistance among Gram-negatives?
Topics: Aminoglycosides; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; beta-Lactamases; Carbapenems; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Indoles; Infection Control; Microbial Sensitivity Tests; Monobactams; Polymyxins; Protein Synthesis Inhibitors | 2011 |
The emerging NDM carbapenemases.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Disease Outbreaks; Enterobacteriaceae; Gene Transfer, Horizontal; Gram-Negative Bacterial Infections; Humans; Plasmids; Pseudomonas; Vibrionaceae | 2011 |
Colistin: new lessons on an old antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials as Topic; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2012 |
Carbapenem-hydrolyzing gram-negative bacteria: current options for treatment and review of drugs in development.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Discovery; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Hydrolysis | 2012 |
Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Carrier State; Cross Infection; Disease Outbreaks; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infection Control; Risk Factors | 2012 |
Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gene Transfer, Horizontal; Global Health; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Plasmids | 2013 |
Extended spectrum beta-lactamases: a therapeutic dilemma.
Topics: Bacteremia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Child; Child, Preschool; Enterobacteriaceae; Female; Gram-Negative Bacterial Infections; Humans; Infant; Male; Microbial Sensitivity Tests; Prognosis; Risk Assessment; Risk Factors; Treatment Outcome | 2002 |
Resistance in gram-negative bacteria: enterobacteriaceae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Resistance, Multiple; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Bacterial Infections; Humans; Klebsiella Infections; Quinolones; Urinary Tract Infections | 2006 |
Beta-lactam resistance in the gram negatives: increasing complexity of conditional, composite and multiply resistant phenotypes.
Topics: Australia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Genotype; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Phenotype; Terminology as Topic | 2006 |
Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Europe; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; North America | 2007 |
Carbapenemases: molecular diversity and clinical consequences.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2007 |
Parenteral carbapenems.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Imipenem; Infusions, Parenteral; Meropenem; Thienamycins | 2008 |
The current state of multidrug-resistant gram-negative bacilli in North America.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Minocycline; North America; Polymyxins; Sulbactam; Tigecycline | 2008 |
Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
Topics: Animals; Carbapenems; Cephalosporins; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Glycylglycine; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Polymyxins | 2008 |
Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Drug Evaluation; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Molecular Structure | 2008 |
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?
Topics: Carbapenems; Central Nervous System Diseases; Clostridioides difficile; Clostridium Infections; Drug Resistance, Bacterial; Drug Resistance, Multiple; Glucose Metabolism Disorders; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heart Diseases; Humans | 2008 |
The role of carbapenems in initial therapy for serious Gram-negative infections.
Topics: Carbapenems; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2008 |
[Metallo-beta-lactamase producing gram negative rods infection].
Topics: beta-Lactamases; Carbapenems; Diagnosis, Differential; Gram-Negative Aerobic Rods and Cocci; Gram-Negative Bacterial Infections; Humans | 1999 |
Extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infection Control; Intensive Care Units; Prevalence; R Factors; Risk Factors | 2000 |
10 trial(s) available for carbapenems and Bacterial Infections, Gram-Negative
Article | Year |
---|---|
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Colistin; Critical Illness; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans | 2020 |
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Topics: Aged; Aged, 80 and over; Carbapenems; Colistin; Cross Infection; Drug Resistance, Bacterial; Drug Synergism; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Sepsis; Urinary Tract Infections; Young Adult | 2021 |
The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Treatment Outcome | 2018 |
Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive ca
Topics: beta-Lactam Resistance; beta-Lactamases; Carbapenems; Deprescriptions; Enterobacteriaceae Infections; Equivalence Trials as Topic; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Mortality; Recurrence; Respiratory Tract Infections; Sepsis; Urinary Tract Infections | 2019 |
Impact of Preemptive Granulocyte Infusions During Febrile Neutropenia in Patients Colonized with Carbapenem-Resistant Gram-Negative Bacteria Undergoing Haploidentical Transplantation.
Topics: Adolescent; Adult; Aged; Allografts; beta-Lactam Resistance; Carbapenems; Child; Child, Preschool; Disease-Free Survival; Febrile Neutropenia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Granulocytes; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukocyte Transfusion; Male; Middle Aged; Prospective Studies; Survival Rate; Time Factors | 2019 |
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins | 2008 |
Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Critical Illness; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Time Factors | 2012 |
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; C-Reactive Protein; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Endotoxemia; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pneumonia, Ventilator-Associated; Sepsis | 2006 |
275 other study(ies) available for carbapenems and Bacterial Infections, Gram-Negative
Article | Year |
---|---|
Emergence of blaNDM-1 and blaVIM producing Gram-negative bacilli in ventilator-associated pneumonia at AMR Surveillance Regional Reference Laboratory in India.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clinical Laboratory Services; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Young Adult | 2021 |
Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Polymyxin B; Retrospective Studies | 2021 |
Using Molecular Diagnostics to Develop Therapeutic Strategies for Carbapenem-Resistant Gram-Negative Infections.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Microbial Sensitivity Tests; Pathology, Molecular | 2021 |
Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain.
Topics: Aftercare; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Patient Discharge; Pneumonia, Bacterial; Retrospective Studies; Spain; Urinary Tract Infections; Ventilators, Mechanical | 2021 |
A host-directed macrocyclic peptide therapeutic for MDR gram negative bacterial infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cytokines; Drug Design; Drug Resistance, Multiple, Bacterial; Escherichia coli; Female; Gram-Negative Bacterial Infections; Humans; Inflammation; Klebsiella pneumoniae; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peptides; Phagocytosis; Sepsis | 2021 |
Environmental spreading of clinically relevant carbapenem-resistant gram-negative bacilli: the occurrence of bla
Topics: Bacterial Proteins; beta-Lactamases; Brazil; Carbapenems; Catchment Area, Health; Drug Resistance, Bacterial; Environmental Monitoring; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitalization; Hospitals, District; Humans; Sewage; Water Microbiology; Water Purification | 2022 |
Prevalence and characterization of antimicrobial resistance among gram-negative bacteria isolated from febrile hospitalized patients in central Ethiopia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Ethiopia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Male; Middle Aged; Prevalence; Young Adult | 2022 |
Acquisition of carbapenem-resistant gram-negative bacilli among intensive care unit (ICU) patients with no previous use of carbapenems: Indirect population impact of antimicrobial use.
Topics: Anti-Bacterial Agents; Carbapenems; Cohort Studies; Cross Infection; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units | 2022 |
Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective.
Topics: Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pneumonia, Ventilator-Associated | 2022 |
A Longitudinal Study of Spontaneous Gut Decolonization of Carbapenem-resistant Gram-negative Bacteria in Neonatal and Pediatric Patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Child; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Longitudinal Studies; Retrospective Studies | 2022 |
Genome-wide identification of carbapenem-resistant Gram-negative bacterial (CR-GNB) isolates retrieved from hospitalized patients in Bihar, India.
Topics: Anti-Bacterial Agents; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Escherichia coli; Gram-Negative Bacterial Infections; Humans; India; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Epidemiology, Outcomes and Resource Utilisation in Patients with Carbapenem Non-susceptible Gram-Negative Bacteria in the UK: A Retrospective, Observational Study (CARBAR UK).
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Retrospective Studies; United Kingdom | 2022 |
Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Watchful Waiting | 2022 |
Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.
Topics: Anti-Infective Agents; Carbapenems; Cohort Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Neutropenia; Piperacillin; Retrospective Studies; Tazobactam; Transplantation, Homologous | 2023 |
Investigation and analysis of carbapenem-resistant gram-negative bacterial infection rates across hospitals in Shandong Province in China.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans | 2022 |
Use of hospital resources in ICU inpatients with infections caused by carbapenem-resistant Gram-negative bacteria: A real clinical practice-based study in Spain.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Inpatients; Intensive Care Units; Male; Middle Aged; Retrospective Studies; Spain | 2023 |
A carbapenem-focused antimicrobial stewardship programme implemented during the COVID-19 pandemic in a setting of high endemicity for multidrug-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; COVID-19; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Pandemics | 2023 |
Carbapenem-resistant gram-negative bacterial infection in intensive care unit patients: Antibiotic resistance analysis and predictive model development.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Retrospective Studies | 2023 |
Risk Factors for Infection and Mortality Associated With Stenotrophomonas maltophilia Bloodstream Infections in Children; Comparison With Pseudomonas aeruginosa Bloodstream Infections.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Child; Gram-Negative Bacterial Infections; Humans; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Sepsis; Stenotrophomonas maltophilia | 2023 |
Interactions of hydrolyzed β-lactams with the L1 metallo-β-lactamase: Crystallography supports stereoselective binding of cephem/carbapenem products.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Crystallography; Gram-Negative Bacterial Infections; Humans; Kinetics; Stenotrophomonas maltophilia | 2023 |
Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Retrospective Studies; Salvage Therapy | 2023 |
Modifiable risk factors associated with later gut decolonization of carbapenem-resistant Gram-negative bacteria in children: a prospective cohort study.
Topics: Anti-Bacterial Agents; Carbapenems; Child; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Prospective Studies; Risk Factors | 2023 |
Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Ceftazidime; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Kidney Diseases; Microbial Sensitivity Tests; Retrospective Studies | 2023 |
Active screening and patient-placement and cohort-placement strategies to decrease carbapenem-resistant gram-negative bacilli colonization and infection in pediatric patients: A 5-year retrospective observational study in China.
Topics: Anti-Bacterial Agents; Carbapenems; Child; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Retrospective Studies | 2023 |
Risk factors of carbapenem-resistant gram-negative bacteria pneumonia and mortality.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pneumonia, Bacterial; Retrospective Studies; Risk Factors | 2022 |
Risk of relapse and readmission among hospitalized adults with carbapenem non-susceptible gram-negative infections.
Topics: Adult; Aftercare; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacterial Infections; Humans; Patient Discharge; Patient Readmission; Retrospective Studies; Urinary Tract Infections | 2023 |
Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Critical Illness; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Polymyxin B; Polymyxins; Retrospective Studies | 2023 |
Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Drug Combinations; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Polymyxin B; Retrospective Studies | 2023 |
Risk factors for colonization with multidrug-resistant Gram-negative bacteria and
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Clostridioides; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Long-Term Care; Prevalence; Risk Factors | 2023 |
High Burden of Intestinal Colonization With Antimicrobial-Resistant Bacteria in Chile: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Carbapenems; Cephalosporins; Chile; COVID-19; Drug Resistance, Microbial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Risk Factors | 2023 |
Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort.
Topics: Anti-Bacterial Agents; Carbapenems; COVID-19; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Polymyxins; Retrospective Studies; Sepsis | 2023 |
Risk factors for nosocomial rectal colonisation with carbapenem-resistant Gram-negative bacilli in children with haematological malignancies: a case-control study.
Topics: Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Child; Cross Infection; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Leukemia, Myeloid, Acute; Risk Factors; Tertiary Care Centers | 2023 |
Impact of carbapenem-targeted antimicrobial stewardship interventions: an interrupted time-series analysis.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2023 |
Prevalence of Antimicrobial Resistance in Gram-Negative Bacteria Bloodstream Infections in Peru and Associated Outcomes: VIRAPERU Study.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Peru; Prevalence; Pseudomonas aeruginosa; Sepsis | 2023 |
Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience.
Topics: Acinetobacter Infections; Aged; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Retrospective Studies | 2023 |
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Leadership; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Europe; European Union; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sentinel Surveillance | 2019 |
Characterisation of carbapenem-resistant Gram-negative organisms from clinical specimens in Yola, Nigeria.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Nigeria | 2020 |
Multidrug-resistant profile and prevalence of extended spectrum β-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Ethiopia; Fermentation; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Prevalence; Prospective Studies | 2019 |
Evaluation of the Direct MacConkey Method for Identification of Carbapenem-Resistant Gram-Negative Organisms from Rectal Swabs: Reevaluating Zone Diameter Cutoffs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Rectum; ROC Curve; Sensitivity and Specificity | 2019 |
Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Klebsiella pneumoniae; Liver Transplantation; Male; Retrospective Studies; Tigecycline; Treatment Outcome | 2020 |
Infection control management and surveillance of carbapenem-resistant Gram-negative bacteria in hematopoietic stem cell recipients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Male; Middle Aged; Prevalence; Public Health Surveillance; Transplant Recipients | 2019 |
Risk factors for development of aminoglycoside resistance among gram-negative rods.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Algorithms; Aminoglycosides; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Patient Transfer; Respiration, Artificial; Retrospective Studies; Risk Factors; Sex Factors; Weight Loss; Young Adult | 2019 |
Mortality risk of bloodstream infection caused by either Escherichia coli or Klebsiella pneumoniae producing extended-spectrum β-lactamase: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Bacteremia; beta-Lactamases; Carbapenems; Child; Child, Preschool; Escherichia coli; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Klebsiella pneumoniae; Male; Middle Aged; Prospective Studies; Risk Factors; Survival Rate | 2019 |
Quercetin inhibits carbapenemase and efflux pump activities among carbapenem-resistant Gram-negative bacteria.
Topics: Amino Acids; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Molecular Docking Simulation; Quercetin | 2020 |
Risk factors for acute kidney injury in critically ill patients with bacteraemia by carbapenem non-susceptible Gram negative bacteria.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Colistin; Critical Illness; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors | 2019 |
Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta-lactamase-producing Gram-negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; France; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Predictive Value of Tests; Prevalence; Retrospective Studies; Risk Factors | 2020 |
The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Hospitalization; Humans; Male; Meropenem; Middle Aged; Organ Dysfunction Scores; Philippines; Respiratory Tract Infections; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Young Adult | 2020 |
Impact of Difficult-to-Treat Resistance in Gram-negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Retrospective Studies | 2020 |
Drivers of press media response to healthcare-associated infections caused by multidrug-resistant organisms: A report from Brazil.
Topics: Acinetobacter baumannii; Brazil; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacterial Infections; Health Policy; Humans; Mass Media | 2020 |
Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017.
Topics: Age Distribution; Anti-Bacterial Agents; Carbapenems; Ceftazidime; Child, Preschool; China; Clavulanic Acids; Comorbidity; Female; Gram-Negative Bacterial Infections; Hospitalization; Humans; Immunosuppressive Agents; Infant; Intensive Care Units, Pediatric; Length of Stay; Male; Piperacillin, Tazobactam Drug Combination; Respiration, Artificial; Retrospective Studies; Risk Factors; Sex Distribution; Stenotrophomonas maltophilia; Surgical Procedures, Operative; Ticarcillin; Trimethoprim, Sulfamethoxazole Drug Combination | 2020 |
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Canada; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Siderophores; Stenotrophomonas maltophilia | 2020 |
Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbapenems; Case-Control Studies; Drug Resistance, Bacterial; Female; Follow-Up Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Health Care Costs; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Prognosis; Respiratory Tract Infections; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; China; Cross-Sectional Studies; Drug Resistance, Bacterial; Drug Utilization; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Penicillins; Retrospective Studies; Tertiary Care Centers | 2020 |
Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Cross-Sectional Studies; Drug Utilization; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Impatiens; Male; Middle Aged; North America; Retrospective Studies; Treatment Outcome | 2020 |
Risk factors for and clinical outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia.
Topics: Acinetobacter baumannii; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Carbapenems; Case-Control Studies; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Odds Ratio; Retrospective Studies; Risk Factors; Tertiary Care Centers; Treatment Outcome | 2020 |
A highly multiplexed melt-curve assay for detecting the most prevalent carbapenemase, ESBL, and AmpC genes.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Molecular Diagnostic Techniques; Multiplex Polymerase Chain Reaction; Sensitivity and Specificity | 2020 |
Shedding of multidrug-resistant gram-negative bacilli by colonized patients during procedures and patient care activities.
Topics: Anti-Bacterial Agents; Carbapenems; Cohort Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Patient Care | 2020 |
Evidence in Microbiome Science: Standards for the Field (and Laboratory).
Topics: Carbapenems; Gram-Negative Bacterial Infections; Humans; Laboratories; Leukemia, Myeloid, Acute; Microbiota; Stenotrophomonas maltophilia | 2021 |
Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy.
Topics: Carbapenems; Gram-Negative Bacterial Infections; Humans; Leukemia, Myeloid, Acute; Microbiota; Prospective Studies; RNA, Ribosomal, 16S; Stenotrophomonas maltophilia | 2021 |
Implementing carbapenem-resistance testing algorithms for Enterobacteriales and Pseudomonas aeruginosa: diagnostic and antimicrobial stewardship with timely infection prevention.
Topics: Algorithms; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Clinical Laboratory Techniques; Drug Resistance, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Middle Aged; Pseudomonas aeruginosa | 2020 |
Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Spain | 2021 |
Temporal association between carbapenems usage and antimicrobial resistance in gram-negative bacteria at a tertiary hospital in Nanjing, China.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Ceftazidime; China; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Utilization; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inpatients; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers | 2020 |
The occurrence of Salmonella, extended-spectrum β-lactamase producing Escherichia coli and carbapenem resistant non-fermenting Gram-negative bacteria in a backyard poultry flock environment.
Topics: Aged; Animal Husbandry; Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Chickens; Child, Preschool; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Housing, Animal; Humans; Salmonella; Salmonella Infections, Animal; Surveys and Questionnaires | 2020 |
Metagenomic next-generation sequencing of rectal swabs for the surveillance of antimicrobial-resistant organisms on the Illumina Miseq and Oxford MinION platforms.
Topics: Carbapenems; Drug Resistance, Bacterial; Genome, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Metagenomics; Rectum; Vancomycin-Resistant Enterococci | 2021 |
Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Brazil; Carbapenems; Case-Control Studies; Critical Illness; Cross Infection; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Sepsis; Tertiary Care Centers; Young Adult | 2020 |
The stability of carbapenems before and after admixture to PMMA-cement used for replacement surgery caused by Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Arthroplasty, Replacement; Austria; Bone Cements; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Polymethyl Methacrylate; Prosthesis-Related Infections | 2020 |
Epidemiologic, Phenotypic, and Structural Characterization of Aminoglycoside-Resistance Gene
Topics: Acetyltransferases; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Catalytic Domain; Databases, Genetic; Drug Resistance, Bacterial; Genome, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Methyltransferases; Molecular Epidemiology; Mutagenesis, Site-Directed; Nebramycin; Standard of Care; Structure-Activity Relationship | 2020 |
Clinical efficacy and safety of novel carbapenem/β-lactamase inhibitor combinations against carbapenem-non-susceptible Gram-negative bacterial infection.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Gram-Negative Bacterial Infections; Humans; Treatment Outcome | 2020 |
Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017.
Topics: Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Retrospective Studies | 2021 |
Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: "Every day matters".
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cohort Studies; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitalization; Humans; Male; Middle Aged; New York; Patient Discharge; Retrospective Studies; Time-to-Treatment; Young Adult | 2020 |
Evaluation of a polymyxin drop test for polymyxin resistance detection among non-fermentative gram-negative rods and enterobacterales resistant to carbapenems.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Polymyxin B | 2021 |
Multicenter Evaluation of Xpert Carba-R Assay for Detection and Identification of the Carbapenemase Genes in Rectal Swabs and Clinical Isolates.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Female; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Diagnostic Techniques; Real-Time Polymerase Chain Reaction; Rectum; Reproducibility of Results; Sensitivity and Specificity | 2021 |
Early identification and optimal management of carbapenem-resistant Gram-negative infection.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Consensus; Drug Resistance, Bacterial; France; Germany; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Infection Control; Italy; Spain; United Kingdom | 2021 |
Healthcare resource use in hospitalized patients with carbapenem-resistant Gram-negative infections.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Delivery of Health Care; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Health Care Costs; Hospitalization; Humans; Inpatients; London; Retrospective Studies | 2021 |
Nosocomial Non-fermentative gram negative bacteria bloodstream infections in children; Risk factors and clinical outcomes of carbapenem resistance.
Topics: Anti-Bacterial Agents; Carbapenems; Child; Cross Infection; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Retrospective Studies; Risk Factors; Sepsis | 2021 |
Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.
Topics: Adult; Aged; beta-Lactam Resistance; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Follow-Up Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Liver Cirrhosis; Liver Transplantation; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Prevalence; Prospective Studies; Retrospective Studies; Staphylococcal Infections; Tertiary Care Centers; Vancomycin-Resistant Enterococci | 2021 |
Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Multiple Organ Failure; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome | 2021 |
Detection of diverse carbapenem and multidrug resistance genes and high-risk strain types among carbapenem non-susceptible clinical isolates of target gram-negative bacteria in Kenya.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Genes, Bacterial; Genes, MDR; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Kenya | 2021 |
Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from Pakistan.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Colistin; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pakistan; Prospective Studies; Treatment Outcome | 2021 |
Drug resistance phenotypes and genotypes in Mexico in representative gram-negative species: Results from the infivar network.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Genes, Bacterial; Genotype; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Mexico; Microbial Sensitivity Tests; Phenotype | 2021 |
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Topics: Adult; Aged; Allografts; Anti-Bacterial Agents; Autografts; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Retrospective Studies; Tazobactam; Treatment Outcome; Young Adult | 2021 |
Detection and characterization of carbapenem resistant Gram-negative bacilli isolates recovered from hospitalized patients at Soba University Hospital, Sudan.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Sudan | 2021 |
Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations.
Topics: Anti-Bacterial Agents; Carbapenems; Cross-Sectional Studies; Developed Countries; Developing Countries; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2022 |
Trends and correlation between antibacterial consumption and carbapenem resistance in gram-negative bacteria in a tertiary hospital in China from 2012 to 2019.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Burkholderia cepacia; Carbapenems; Cephalosporins; China; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Linear Models; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers; Tetracyclines | 2021 |
Characterization of carbapenem-resistant gram-negative bacterial isolates from Nigeria by whole genome sequencing.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Genome, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Nigeria | 2021 |
Combined selective culture and molecular methods for the detection of carbapenem-resistant organisms from fecal specimens.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colony Count, Microbial; Cross Infection; Drug Resistance, Bacterial; Feces; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Polymerase Chain Reaction; Sensitivity and Specificity | 2021 |
Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Stenotrophomonas maltophilia | 2021 |
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inpatients; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Pseudomonas aeruginosa; Thienamycins; Tigecycline | 2017 |
The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease.
Topics: Adult; Aged; Aged, 80 and over; Carbapenems; Chi-Square Distribution; Drug Resistance, Multiple, Bacterial; Female; Germany; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sepsis; Time Factors; Treatment Outcome; Young Adult | 2017 |
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Dogs; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Mice; Models, Molecular; Penicillin-Binding Proteins; Rats; Sulbactam | 2017 |
Current problematic and emergence of carbapenemase-producing bacteria: a brief report from a Libyan hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Libya; Microbial Sensitivity Tests | 2017 |
Impact of a Carbapenem Antimicrobial Stewardship Program on Patient Outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Child; Child, Preschool; Drug Utilization; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Inappropriate Prescribing; Infant; Infant, Newborn; Middle Aged; Prescriptions; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Case-Control Studies; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Propensity Score; Retrospective Studies; Risk Factors; Treatment Outcome | 2018 |
Sustained pediatric antimicrobial stewardship program with consultation to infectious diseases reduced carbapenem resistance and infection-related mortality.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Child; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Japan; Pseudomonas aeruginosa; Referral and Consultation; Tokyo | 2017 |
The prospective evaluation of risk factors and clinical influence of carbapenem resistance in children with gram-negative bacteria infection.
Topics: Carbapenems; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Risk Factors | 2018 |
Colistin Area Under the Time-Concentration in Children Treated With Intravenous Loading Dose and Maintenance Therapy.
Topics: Adolescent; Anti-Bacterial Agents; Area Under Curve; Carbapenems; Child; Child, Preschool; Colistin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Injections, Intravenous; Underage Drinking | 2018 |
Impact of Penicillin Allergy on Empirical Carbapenem Use in Gram-Negative Bloodstream Infections: An Antimicrobial Stewardship Opportunity.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Bacteremia; Carbapenems; Cohort Studies; Drug Hypersensitivity; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Penicillins; Practice Patterns, Physicians'; Retrospective Studies; Time Factors | 2018 |
Clinical predictors of Stenotrophomonas maltophilia bacteremia in adult patients with hematologic malignancy.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Case-Control Studies; Cross Infection; Female; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Immunocompromised Host; Male; Middle Aged; Multivariate Analysis; Pneumonia; Prognosis; Stenotrophomonas maltophilia; Survival Analysis; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Colistin; Cross Infection; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies | 2018 |
β LACTA testing may not improve treatment decisions made with MALDI-TOF MS-informed antimicrobial stewardship advice for patients with Gram-negative bacteraemia: a prospective comparative study.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Bacteremia; beta-Lactamases; Carbapenems; Clinical Decision-Making; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Prospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Colombia; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Female; Gram-Negative Bacterial Infections; Health Care Costs; Humans; Intraabdominal Infections; Klebsiella pneumoniae; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Surgical Wound Infection | 2018 |
Prospective evaluation of risk factors and clinical influence of carbapenem resistance in children with gram-negative bacteria infection: Methodologic issues.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Prospective Studies; Research Design; Risk Factors | 2018 |
Response to a letter to the Editor regarding the prospective evaluation of risk factors and clinical influence of carbapenem resistance in children with gram-negative bacteria infection.
Topics: Anti-Bacterial Agents; Carbapenems; Child; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Risk Factors | 2018 |
Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and Questionnaires | 2018 |
[Identification of anaerobic gram-negative bacilli isolated from various clinical specimens and determination of antibiotic resistance profiles with E-test methods].
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2018 |
Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Carbapenems; Cross Infection; Female; Germany; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Male; Microbial Sensitivity Tests; Prevalence; Retrospective Studies; Treatment Outcome | 2018 |
Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inpatients; Sepsis | 2018 |
Impact of active surveillance and infection control measures on carbapenem-resistant Gram-negative bacterial colonization and infections in intensive care.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Critical Illness; Epidemiological Monitoring; Female; Gram-Negative Bacterial Infections; Humans; Incidence; Infection Control; Intensive Care Units; Klebsiella pneumoniae; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Prevalence; Prospective Studies; Pseudomonas aeruginosa; Retrospective Studies; Young Adult | 2018 |
Multicenter Evaluation of the Xpert Carba-R Assay for Detection of Carbapenemase Genes in Gram-Negative Isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Illinois; Italy; Microbial Sensitivity Tests; Molecular Diagnostic Techniques; Oregon; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Spain; Time Factors | 2018 |
Integrons and insertion sequence common region 1 (ISCR1) of carbapenem-non-susceptible Gram-negative bacilli in fecal specimens from 5000 patients in southern China.
Topics: beta-Lactam Resistance; Carbapenems; China; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Feces; Gene Order; Genes, Bacterial; Genotype; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Integrons | 2018 |
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Databases, Factual; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; Prognosis; Retrospective Studies; Treatment Outcome; United States; Young Adult | 2018 |
Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Catheter-Related Infections; Cross Infection; Female; Gram-Negative Bacterial Infections; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; United States; Urinary Tract Infections | 2018 |
A prognostic score for the resolution of bacteremia by Gram-negative bacteria resistant to carbapenems.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Biomarkers; Carbapenems; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Odds Ratio; Prognosis | 2018 |
Warning: spread of NDM-1 in two border towns of Iran.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Enterobacter; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Iran; Klebsiella pneumoniae | 2018 |
Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Chryseobacterium; Drug Resistance, Bacterial; Female; Flavobacteriaceae Infections; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Kaplan-Meier Estimate; Male; Microbial Sensitivity Tests; Middle Aged; Odds Ratio; Pseudomonas aeruginosa; Retrospective Studies; Stenotrophomonas maltophilia; Taiwan; Tertiary Care Centers | 2019 |
Impact of an infectious diseases specialist-led antimicrobial stewardship programmes on antibiotic use and antimicrobial resistance in a large Korean hospital.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Cephalosporins; Drug Prescriptions; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Escherichia coli; Fluoroquinolones; Glycopeptides; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospital Mortality; Hospitals; Humans; Intensive Care Units; Klebsiella pneumoniae; Physicians; Pseudomonas aeruginosa; Republic of Korea; Specialization; Staphylococcus aureus | 2018 |
A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 β-lactamase.
Topics: Aeromonas hydrophila; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Bile; Carbapenems; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Genes, Bacterial; Genome, Bacterial; Gram-Negative Bacterial Infections; Hospitalization; Humans; Japan; Microbial Sensitivity Tests; Sequence Analysis, DNA | 2018 |
Carbapenem-resistant Gram-negative bloodstream infections in critically ill children: outcome and risk factors in a tertiary teaching hospital in South America.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Child; Child, Preschool; Critical Illness; Female; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; Infant; Male; Risk Factors; South America; Survival Analysis; Tertiary Care Centers; Treatment Outcome | 2019 |
High frequency and molecular epidemiology of metallo-β-lactamase-producing gram-negative bacilli in a tertiary care hospital in Lahore, Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamases; Carbapenems; Child; Child, Preschool; Cross Infection; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Pakistan; Public Health Surveillance; Tertiary Care Centers; Young Adult | 2018 |
Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; China; Drug Resistance, Bacterial; Drug Utilization; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Penicillins; Prevalence; Pseudomonas aeruginosa; Quinolones; Retrospective Studies; Tertiary Care Centers | 2018 |
Multidrug-Resistant Gram-Negative Bacilli: A Retrospective Study of Trends in a Tertiary Healthcare Unit.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Bronchoalveolar Lavage; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Intensive Care Units; Retrospective Studies; Risk Factors; Romania; Surgery Department, Hospital; Tertiary Healthcare | 2018 |
Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cost of Illness; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Health Care Costs; Humans; Length of Stay; Male; Middle Aged; Prevalence; Survival Analysis; Urinary Tract Infections; Young Adult | 2019 |
Novel Antibiotics in the Treatment of Urinary Tract Infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Clinical Trials as Topic; Cystitis; Drug Resistance, Bacterial; Drug Therapy, Combination; Drug Utilization; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Iatrogenic Disease; Tetracyclines; Urinary Tract Infections | 2019 |
Prevalence of metallo-β-lactamase acquired genes among carbapenems susceptible and resistant Gram-negative clinical isolates using multiplex PCR, Khartoum hospitals, Khartoum Sudan.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Multiplex Polymerase Chain Reaction; Prevalence; Pseudomonas aeruginosa; Sudan | 2018 |
Multidrug resistant Gram-negative infections in neonatology.
Topics: Carbapenems; Cohort Studies; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Male; Retrospective Studies | 2019 |
A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study.
Topics: Algorithms; beta-Lactam Resistance; Carbapenems; Costs and Cost Analysis; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Length of Stay; Male; Middle Aged; Outcome and Process Assessment, Health Care; Pneumonia, Ventilator-Associated; Retrospective Studies; Survival Analysis; United States | 2019 |
Multiple colonization with carbapenem-resistant Gram-negative bacteria acquired in India and transferred to Switzerland.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; India; Male; Middle Aged; Switzerland; Treatment Outcome | 2019 |
Effect of short-term carbapenem restriction on the incidence of non-pseudomonal multi-drug resistant Gram-negative bacilli in an intensive care unit.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Retrospective Studies; Saudi Arabia; Withholding Treatment | 2019 |
Predicting acquisition of carbapenem-resistant Gram-negative pathogens in intensive care units.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Brazil; Carbapenems; Case-Control Studies; Clinical Decision Rules; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Intensive Care Units; Male; Middle Aged; Risk Factors; Survival Analysis; Young Adult | 2019 |
Phenotypic and Genotypic Characterization of Carbapenem-Resistant Gram-Negative Bacilli Pathogens from Hospitals in Ghana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Female; Genotype; Ghana; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Phenotype; Young Adult | 2019 |
Forecasting models of infections due to carbapenem-resistant Gram-negative bacteria in an intensive care unit in an endemic area.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Aged, 80 and over; Bayes Theorem; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Klebsiella pneumoniae; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Models, Theoretical; Pseudomonas aeruginosa; Retrospective Studies; Seasons; Young Adult | 2020 |
Evaluation of the Immunochromatographic NG-Test Carba 5 for Rapid Identification of Carbapenemase in Nonfermenters.
Topics: Achromobacter denitrificans; Acinetobacter; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Chromatography, Affinity; France; Gene Expression; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas; Sensitivity and Specificity; Species Specificity | 2019 |
Antibiotics with activity against intestinal anaerobes and the hazard of acquired colonization with ceftriaxone-resistant Gram-negative pathogens in ICU patients: a propensity score-based analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Intestines; Male; Meropenem; Middle Aged; Propensity Score; Retrospective Studies | 2019 |
Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings?
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Communicable Disease Control; Drug Resistance, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; Pseudomonas aeruginosa | 2013 |
"Down the drain": carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks.
Topics: Australia; beta-Lactamases; Carbapenems; Confidence Intervals; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Enterobacteriaceae; Equipment and Supplies, Hospital; Equipment Contamination; Female; Gram-Negative Bacterial Infections; Hand Disinfection; Humans; Incidence; Infection Control; Intensive Care Units; Male; Microbial Sensitivity Tests; Risk Assessment | 2013 |
Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Prevalence; Taiwan | 2013 |
Detection of IMP metallo-β-lactamase in carbapenem-nonsusceptible Enterobacteriaceae and non-glucose-fermenting Gram-negative rods by immunochromatography assay.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Chromatography, Affinity; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Japan; Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA | 2013 |
Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients.
Topics: Bacteremia; beta-Lactam Resistance; Carbapenems; Case-Control Studies; Cross Infection; Female; Gram-Negative Bacterial Infections; Greece; Humans; Intensive Care Units; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Risk Factors | 2013 |
The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
Topics: Adolescent; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Carbapenems; Child; Cystic Fibrosis; Disease Progression; Doripenem; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas stutzeri; Rhodospirillaceae; Thienamycins; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Evaluation of brilliance CRE agar for the detection of carbapenem-resistant gram-negative bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Colony Count, Microbial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2013 |
Emergence of VIM-6 metallo-beta-lactamase-producing Alcaligenes faecalis clinical isolates in a hospital in India.
Topics: Alcaligenes faecalis; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA, Bacterial; Gram-Negative Bacterial Infections; Hospitals; Humans; India; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2013 |
History of antibiotics: from fluoroquinolones to daptomycin (Part 2).
Topics: Anti-Bacterial Agents; Carbapenems; Daptomycin; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; History, 20th Century; Methicillin-Resistant Staphylococcus aureus; Oxazolidinones; Vancomycin | 2013 |
Faecal carriage of ESBL-producing Enterobacteriaceae and carbapenem-resistant Gram-negative bacilli in community settings.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Carrier State; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Feces; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; Young Adult | 2013 |
Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, General; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Singapore; Thienamycins; Young Adult | 2013 |
Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cohort Studies; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Polymyxin B; Prospective Studies; Renal Insufficiency; Rifampin; Survival Analysis; Treatment Outcome | 2014 |
Carbapenem de-escalation therapy in a resource-limited setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Female; Gentian Violet; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Lung Diseases; Male; Middle Aged; Phenazines; Referral and Consultation; Shock, Septic; Thailand; Urinary Tract Infections; Young Adult | 2013 |
Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU.
Topics: Bacteremia; Carbapenems; Cohort Studies; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Male; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Critical Illness; Cross Infection; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Republic of Korea; Retrospective Studies; Risk Factors | 2014 |
High-level and novel mechanisms of carbapenem resistance in Gram-negative bacteria from tertiary hospitals in Nigeria.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cluster Analysis; Conjugation, Genetic; Genotype; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Hydrolysis; Imipenem; Microbial Sensitivity Tests; Molecular Typing; Nigeria; Plasmids; Random Amplified Polymorphic DNA Technique; Sequence Analysis, DNA; Tertiary Care Centers; Transformation, Bacterial | 2014 |
[Pattern dynamics of bacteriemia and sepsis pathogens in ICU patients of emergency service].
Topics: Acetamides; Acinetobacter; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Candida; Candidiasis; Carbapenems; Cefoperazone; Drug Resistance, Multiple, Bacterial; Enterococcus; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Klebsiella pneumoniae; Linezolid; Methicillin; Methicillin-Resistant Staphylococcus aureus; Oxazolidinones; Sepsis; Sulbactam; Vancomycin | 2013 |
NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; United Kingdom | 2014 |
Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Vietnam | 2014 |
[Evolution of antimicrobial resistance in Gram negative bacilli from intensive care units in Colombia].
Topics: Acinetobacter baumannii; Adult; Bacterial Proteins; beta-Lactamases; Carbapenems; Child; Child, Preschool; Colombia; Drug Resistance, Multiple, Bacterial; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Intensive Care Units; Klebsiella pneumoniae; Population Surveillance; Pseudomonas aeruginosa | 2014 |
Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genotype; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Italy; Klebsiella pneumoniae; Microbial Sensitivity Tests; Minocycline; Multilocus Sequence Typing; Tigecycline | 2014 |
Emergence of carbapenemase-producing Gram-negative bacteria in Saint Petersburg, Russia.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cluster Analysis; DNA, Bacterial; Enterobacter cloacae; Genotype; Gram-Negative Bacterial Infections; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Multilocus Sequence Typing; Russia | 2014 |
Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.
Topics: Academic Medical Centers; Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cohort Studies; Colistin; Female; Gram-Negative Bacterial Infections; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; United States | 2015 |
Risk factors for carbapenem resistant bacteraemia and mortality due to gram negative bacteraemia in a developing country.
Topics: Adult; Bacteremia; Carbapenems; Drug Resistance, Bacterial; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Male; Middle Aged; Multivariate Analysis; Pakistan; Prospective Studies; Risk Factors | 2014 |
Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Michigan; Middle Aged; Minocycline; Pharmacy Service, Hospital | 2014 |
Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS).
Topics: Bacterial Infections; beta-Lactam Resistance; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Gram-Negative Bacterial Infections; Humans; Incidence; Intensive Care Units; Methicillin-Resistant Staphylococcus aureus; Population Surveillance; Prevalence; Staphylococcal Infections; Vancomycin-Resistant Enterococci | 2015 |
A prediction tool for nosocomial multi-drug Resistant Gram-Negative Bacilli infections in critically ill patients - prospective observational study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cohort Studies; Critical Illness; Cross Infection; Decision Support Techniques; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Logistic Models; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis; Risk Factors; Surgical Procedures, Operative; Systemic Inflammatory Response Syndrome; Urinary Tract Infections | 2014 |
Molecular characteristics of carbapenem-resistant gram-negative bacteria in southern China.
Topics: Anti-Bacterial Agents; ATP-Binding Cassette Transporters; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Drug Resistance, Bacterial; Genes, Bacterial; Glutathione Transferase; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Integrons; Meropenem; Mutagenesis, Insertional; Thienamycins | 2015 |
Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug Therapy; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Endemic Diseases; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Patient Readmission; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Exploring the epidemiology of carbapenem-resistant Gram-negative bacteria in west London and the utility of routinely collected hospital microbiology data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; London; Male; Middle Aged; Young Adult | 2015 |
Prevalence and clinical burden of NDM-1 positive infections in pediatric and neonatal patients in Pakistan.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child, Preschool; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Pakistan; Polymerase Chain Reaction; Prevalence; Survival Analysis | 2015 |
Next-generation sequencing of carbapenem-resistant Gram-negative microorganisms: a key tool for surveillance and infection control.
Topics: beta-Lactam Resistance; Carbapenems; Epidemiological Monitoring; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; High-Throughput Nucleotide Sequencing; Humans; Infection Control; Sequence Analysis, DNA | 2015 |
Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Cohort Studies; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Italy; Male; Middle Aged; Organ Transplantation; Risk Factors; Transplant Recipients | 2015 |
Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Case-Control Studies; Critical Illness; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Survival Rate; Systemic Inflammatory Response Syndrome | 2015 |
Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria.
Topics: Adult; Aged; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Infant; Male; Middle Aged; Organ Transplantation; Retrospective Studies; Tissue Donors; Treatment Outcome | 2015 |
Characterization of carbapenem-resistant Gram-negative bacteria from Tamil Nadu.
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; India; Microbial Sensitivity Tests | 2016 |
Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Cohort Studies; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis | 2015 |
Prevalence of MRSA and Gram-negative bacteria with ESBLs and carbapenemases in patients from Northern Africa at a German hospital.
Topics: Adult; Africa, Northern; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Female; Genes, Bacterial; Genotype; Germany; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prevalence; Staphylococcal Infections; Transients and Migrants | 2015 |
Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Topics: Acinetobacter baumannii; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Malaysia; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Prospective Studies; Pseudomonas aeruginosa; Sepsis; Survival Analysis | 2016 |
Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Colistin; Drug Administration Schedule; Drug Dosage Calculations; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Case-Control Studies; Child; Child, Preschool; Drug Utilization; Female; Genotype; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; Male; Prospective Studies; Risk Factors; Tertiary Care Centers; Turkey | 2016 |
Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Child; Child, Preschool; Colistin; Enterobacteriaceae; Female; Gram-Negative Bacterial Infections; Humans; India; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Tertiary Care Centers; Treatment Outcome; Young Adult | 2015 |
First the ESBLs, now the Carbapenemases: Where will it End?
Topics: Bacteremia; beta-Lactam Resistance; Carbapenems; Female; Gram-Negative Bacterial Infections; Humans; Male | 2015 |
National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013.
Topics: Anti-Infective Agents; Carbapenems; China; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Prevalence | 2016 |
Genotypic and phenotypic identification of Aeromonas species and CphA-mediated carbapenem resistance in Queensland, Australia.
Topics: Aeromonas; Anti-Bacterial Agents; Australia; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Genotype; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Sensitivity and Specificity | 2016 |
Multiplex real-time PCR assay for the detection of extended-spectrum β-lactamase and carbapenemase genes using melting curve analysis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Multiplex Polymerase Chain Reaction; Real-Time Polymerase Chain Reaction | 2016 |
Anatomic, Geographic, and Taxon-Specific Relative Risks of Carbapenem Resistance in the Health Care System of the U.S. Department of Defense.
Topics: Acinetobacter; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Child; Child, Preschool; Enterobacteriaceae; Female; Geography; Gram-Negative Bacterial Infections; Health Facilities; Humans; Infant; Infant, Newborn; Male; Middle Aged; Military Facilities; Pseudomonas aeruginosa; Risk; United States; Young Adult | 2016 |
Evaluation of Multiple Methods for Detection of Gastrointestinal Colonization of Carbapenem-Resistant Organisms from Rectal Swabs.
Topics: Bacterial Proteins; Bacteriological Techniques; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Rectum; Sensitivity and Specificity | 2016 |
Carbapenem-resistant organisms (CRO): Information for patients, relatives and visitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Health Education; Humans | 2016 |
Carbapenem-resistant organisms (CRO): Information for healthcare workers.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Utilization; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Health Personnel; Humans; Infection Control; Mass Screening | 2016 |
Surveillance of antibiotic susceptibility in a Swedish Burn Center 1994-2012.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Anti-Bacterial Agents; Bacteremia; Burn Units; Burns; Carbapenems; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Klebsiella; Klebsiella Infections; Linear Models; Logistic Models; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Staphylococcal Infections; Sweden; Urinary Tract Infections; Wound Infection; Young Adult | 2016 |
Epidemiological characteristics and antimicrobial susceptibility among carbapenem-resistant non-fermenting bacteria in Brazil.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Brazil; Carbapenems; Child; Child, Preschool; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Male; Middle Aged; Polymerase Chain Reaction; Pseudomonas aeruginosa; Survival Analysis; Young Adult | 2016 |
Boronic acid disk diffusion for the phenotypic detection of polymerase chain reaction-confirmed, carbapenem-resistant, gram-negative bacilli isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Boronic Acids; Carbapenems; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Phenotype; Polymerase Chain Reaction; Thienamycins | 2016 |
High prevalence of hospital-acquired infections caused by gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: A multi-centre point prevalence survey.
Topics: Carbapenems; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Hospitals, Pediatric; Humans; Infant; Intensive Care Units, Pediatric; Male; Prevalence; Vietnam | 2016 |
Carbapenem-resistant gram-negative bacilli in Tripoli, Libya.
Topics: Acinetobacter; Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamases; Carbapenems; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Klebsiella pneumoniae; Libya; Male; Middle Aged; Pseudomonas aeruginosa; Specimen Handling; Young Adult | 2016 |
Screening for carbapenem-resistant organisms.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Disease Transmission, Infectious; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infection Control; Mass Screening | 2016 |
Improving outcomes in the management of Gram-negative bacterial infections in the face of growing antimicrobial resistance.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Congresses as Topic; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella; Netherlands; Population Surveillance; Pseudomonas aeruginosa; Risk Factors; Treatment Outcome | 2016 |
An Antimicrobial Stewardship Program Based on Systematic Infectious Disease Consultation in a Rehabilitation Facility.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antimicrobial Stewardship; Carbapenems; Cross Infection; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Italy; Referral and Consultation; Rehabilitation Centers; Spinal Injuries | 2017 |
The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Cohort Studies; Colistin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Health Status Indicators; Humans; Male; Mortality; Prospective Studies | 2016 |
Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: Risk factors and outcome.
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Carbapenems; Child; Child, Preschool; Cross Infection; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Retrospective Studies; Risk Factors; Tertiary Care Centers | 2017 |
Clinical Characteristics of Stenotrophomonas maltophilia Bacteremia: A Regional Report and a Review of a Japanese Case Series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Carbapenems; Child; Child, Preschool; Cross Infection; Female; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Immunocompromised Host; Infant; Infant, Newborn; Japan; Male; Middle Aged; Retrospective Studies; Stenotrophomonas maltophilia; Young Adult | 2017 |
Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Fever; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Neutropenia; Pakistan; Vancomycin Resistance | 2008 |
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; United States | 2008 |
Trends in Stenotrophomonas maltophilia bloodstream infection in relation to usage density of cephalosporins and carbapenems during 7 years.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactams; Brazil; Carbapenems; Cephalosporins; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Incidence; Stenotrophomonas maltophilia | 2008 |
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Topics: Acinetobacter; Aeromonas; Anti-Bacterial Agents; Bacteria, Aerobic; Carbapenems; Doripenem; Gram-Negative Bacterial Infections; Humans; Latin America; Microbial Sensitivity Tests; North America; Pseudomonas | 2009 |
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2009 |
Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
Topics: beta-Lactamase Inhibitors; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
The emerging threat of acquired carbapenemases in Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Communicable Diseases, Emerging; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2010 |
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic | 2010 |
Factors associated with recovery of multidrug-resistant bacteria in a combat support hospital in Iraq.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Military; Humans; Iraq; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Military Personnel; Risk Factors; Staphylococcal Infections; Staphylococcus aureus; Warfare | 2010 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method | 2010 |
Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2010 |
Carbapenems in the treatment of intra-abdominal infection. Report from the 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, 10-13 April 2010.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Peritonitis | 2010 |
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
Topics: Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins | 2010 |
Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Korea; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Thienamycins; Urinary Tract Infections | 2011 |
Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Topics: Anti-Bacterial Agents; Asia; Australia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Injections, Intravenous; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Thienamycins | 2011 |
Frequency and susceptibility pattern of metallo-beta-lactamase producers in a hospital in Pakistan.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Pakistan | 2010 |
Emergence of metallo-β-lactamases and carbapenem resistance.
Topics: beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cross Infection; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Microbial Sensitivity Tests; Polymyxin B | 2011 |
Comparative activity of carbapenem testing: the COMPACT study.
Topics: Africa; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle East; Thienamycins | 2011 |
Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Rectum; Stenotrophomonas maltophilia; Thienamycins | 2011 |
[Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Turkey | 2011 |
[Actual aspects of sepsis].
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Hospitals; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Retrospective Studies; Russia; Sepsis; Vancomycin | 2011 |
Evaluation of doripenem utilization and susceptibilities at a large urban hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Treatment Failure; Treatment Outcome; Urban Health Services; Young Adult | 2011 |
Prevalence of New Delhi metallo-β-lactamase (NDM-1)-positive bacteria in a tertiary care centre in Pune, India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamases; Carbapenems; Child; Drug Resistance, Bacterial; Female; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; India; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; Young Adult | 2012 |
Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intraabdominal Infections; Microbial Sensitivity Tests; Prevalence; South Africa | 2012 |
Stenotrophomonas maltophilia--the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Cohort Studies; Cross Infection; Drug Resistance, Bacterial; Female; Fermentation; France; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; Intensive Care Units; Male; Middle Aged; Prospective Studies; Risk Factors; Stenotrophomonas maltophilia; Treatment Outcome | 2012 |
Genetic and biochemical characterization of a novel metallo-β-lactamase, TMB-1, from an Achromobacter xylosoxidans strain isolated in Tripoli, Libya.
Topics: Achromobacter denitrificans; Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Chromosomes, Bacterial; DNA, Bacterial; Gram-Negative Bacterial Infections; Humans; Integrons; Kinetics; Libya; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Sequence Alignment; Sequence Homology, Amino Acid | 2012 |
In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Carbapenems; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2012 |
Comparative activity of carbapenem testing (the COMPACT study) in Turkey.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Child; Child, Preschool; Cross Infection; Enterobacteriaceae; Female; Gram-Negative Bacterial Infections; Hospitals; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Turkey; Young Adult | 2012 |
Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cross Infection; Gram-Negative Bacterial Infections; Hospitals; Humans; Infection Control; Klebsiella pneumoniae; Length of Stay; New York City; Prevalence; Pseudomonas aeruginosa | 2012 |
Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
Topics: Anti-Bacterial Agents; Asia; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Geography; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inhibitory Concentration 50; Intensive Care Units; Microbial Sensitivity Tests; Pacific Islands; Population Surveillance; Prevalence | 2012 |
Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP).
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Canada; Carbapenems; Cross Infection; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Molecular Typing; Plasmids; Polymerase Chain Reaction; Prevalence; Sequence Analysis, DNA | 2012 |
Successful treatment with doripenem of ventriculitis due to Achromobacter xylosoxidans.
Topics: Achromobacter denitrificans; Adult; Anti-Bacterial Agents; Carbapenems; Cerebral Ventriculitis; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Treatment Outcome | 2014 |
Proteomic analysis of clinical isolate of Stenotrophomonas maltophilia with blaNDM-1, blaL1 and blaL2 β-lactamase genes under imipenem treatment.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Gene Expression; Gene Expression Regulation, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Phenotype; Proteome; Proteomics; Stenotrophomonas maltophilia | 2012 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.
Topics: Acinetobacter baumannii; Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Probability; Pseudomonas aeruginosa; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
[Last chance for effective antibiotics?].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Internationality; Norway | 2012 |
Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.
Topics: Achromobacter denitrificans; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genes, MDR; Genome, Bacterial; Gram-Negative Bacterial Infections; High-Throughput Nucleotide Sequencing; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Respiratory Tract Infections; Sequence Analysis, DNA | 2013 |
Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins; Time Factors | 2013 |
Carbapenem disks on MacConkey agar in screening methods for detection of carbapenem-resistant Gram-negative rods in stools.
Topics: Agar; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Culture Media; Feces; Gram-Negative Aerobic Rods and Cocci; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2013 |
Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.
Topics: Animals; Anti-Bacterial Agents; Biological Availability; Carbapenems; Community-Acquired Infections; Dipeptidases; Dogs; Drug Stability; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Rabbits; Rats; Rats, Sprague-Dawley | 2013 |
Prosthetic aortic valve endocarditis due to Ochrobactrum anthropi.
Topics: Aged; Aortic Valve; Carbapenems; Endocarditis, Bacterial; Gram-Negative Bacterial Infections; Humans; Male; Ochrobactrum anthropi | 2011 |
Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children.
Topics: Acinetobacter; Acinetobacter Infections; Adolescent; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Child; Child, Hospitalized; Child, Preschool; Cross Infection; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Klebsiella; Klebsiella Infections; Male; Pseudomonas; Pseudomonas Infections; Survival Analysis | 2013 |
[Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Topics: Carbapenems; Cefozopran; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Monobactams; Penicillins; Product Surveillance, Postmarketing; Time Factors | 2003 |
Genetic and biochemical characterization of a chromosome-encoded carbapenem-hydrolyzing ambler class D beta-lactamase from Shewanella algae.
Topics: Amino Acid Sequence; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Child; Chromosomes, Bacterial; Cloning, Molecular; Conjugation, Genetic; DNA, Bacterial; Escherichia coli; Female; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillinase; Phenotype; Plasmids; Shewanella | 2004 |
Clinical experiences of bacteremia caused by metallo-beta-lactamase-producing gram-negative organisms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Carbapenems; Child; Child, Preschool; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged | 2004 |
In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Mice; Microbial Sensitivity Tests | 2005 |
Incidence of carbapenem resistant nonfermenting gram negative bacilli from patients with respiratory infections in the intensive care units.
Topics: beta-Lactam Resistance; Carbapenems; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence; India; Intensive Care Units; Respiratory Tract Infections | 2005 |
Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactams; Carbapenems; Drug Resistance, Microbial; Ertapenem; Gram-Negative Anaerobic Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inhibitory Concentration 50; Metronidazole; Microbial Sensitivity Tests | 2005 |
Detection of metallo beta-lactamase production and antibiotic resistance with E-test method in pseudomonas, acinetobacter and klebsiella strains, in Turkey.
Topics: Acinetobacter baumannii; Adult; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Turkey | 2004 |
In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
Topics: Abscess; Animals; Anti-Bacterial Agents; Area Under Curve; Carbapenems; Enterococcus faecalis; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Infusions, Parenteral; Kinetics; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Molecular Structure; Reference Standards | 2005 |
Acquired metallo-beta-lactamases: an increasing clinical threat.
Topics: Anti-Bacterial Agents; Australia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cross Infection; Disease Outbreaks; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2005 |
Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Australia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cross Infection; Disease Outbreaks; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged | 2005 |
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; Incidence; Length of Stay; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Taiwan | 2005 |
Epidemiology of extended-spectrum beta-lactamase producing gram-negative bacilli at Siriraj Hospital, Thailand, 2003.
Topics: beta-Lactamases; Carbapenems; Cross Infection; Cross-Sectional Studies; Disease Susceptibility; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitalization; Humans; Male; Middle Aged; Prevalence; Risk Assessment; Risk Factors; Thailand; Treatment Outcome | 2005 |
[Antimicrobial susceptibilities of organisms isolated from patients with urinary tract infections in 2002].
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Enterobacteriaceae; Enterococcus; Enterococcus faecalis; Escherichia coli; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Humans; Pseudomonas aeruginosa; Staphylococcus; Staphylococcus aureus; Urinary Tract Infections | 2006 |
Screening for antibiotic resistant Gram-negative bacteria.
Topics: Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infection Control | 2006 |
The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants.
Topics: Blood; Candidiasis; Carbapenems; Catheterization, Central Venous; Central Nervous System Fungal Infections; Cephalosporins; Cerebrospinal Fluid; Comorbidity; Cross Infection; Enterocolitis, Necrotizing; Fungemia; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Prospective Studies; Registries; Risk Factors; Superinfection | 2006 |
Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteriological Techniques; beta-Lactamases; Carbapenems; Culture Media; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Laboratories; Microbial Sensitivity Tests; Phenotype; Polymerase Chain Reaction; Pseudomonas; Sensitivity and Specificity | 2006 |
Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units).
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Drug Utilization Review; Fluoroquinolones; Germany; Glycopeptides; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Risk Factors; Sentinel Surveillance; Stenotrophomonas maltophilia | 2006 |
In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Enterobacteriaceae; Ertapenem; Gram-Negative Bacterial Infections; Humans; Imipenem; Klebsiella; Meropenem; Microbial Sensitivity Tests; Proteus; Sweden; Thienamycins | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Resistance, Multiple; Empiricism; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospitals, Teaching; Humans; Intensive Care Units; Male; Middle Aged; Missouri; Penicillins; Pneumonia, Bacterial; Prospective Studies; Survival Rate; Urinary Tract Infections; Ventilators, Mechanical | 2006 |
Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.
Topics: Adult; Aged; Bacteremia; Carbapenems; Case-Control Studies; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Mortality; Neoplasms; Neutropenia; Pneumonia, Bacterial; Retrospective Studies; Risk Factors; Stenotrophomonas maltophilia; Texas | 2007 |
Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Brazil; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infant; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Prospective Studies; Risk Factors | 2007 |
One year trends in the gram-negative bacterial antibiotic susceptibility patterns in a medical intensive care unit in South India.
Topics: Carbapenems; Cefotaxime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; India; Intensive Care Units; Microbial Sensitivity Tests | 2007 |
[Resistance epidemiology of gramnegative nonfermenting pathogens of nosocomial infections in intensive care units and surgical departments].
Topics: Acinetobacter baumannii; Adolescent; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefoperazone; Child; Child, Preschool; Cross Infection; Drug Resistance, Microbial; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Infant; Intensive Care Units; Microbial Sensitivity Tests; Molecular Epidemiology; Moscow; Pseudomonas aeruginosa; Sulbactam; Surgery Department, Hospital | 2006 |
[Imipenem resistance in Gram-negative rods and its consumption between 1999 and 2005].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; Carbapenems; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests; Retrospective Studies | 2007 |
Nosocomial bloodstream infection in a pediatric intensive care unit.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Child; Child, Preschool; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitals, Teaching; Humans; Incidence; India; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Medical Records; Microbial Sensitivity Tests; Retrospective Studies; Treatment Outcome; Vancomycin | 2008 |
Optimizing the use of carbapenems in the face of increasing Gram-negative resistance.
Topics: Carbapenems; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2008 |
PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams.
Topics: Alcaligenes; Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; Base Sequence; beta-Lactamases; Carbapenems; Ceftazidime; Cross Infection; DNA Primers; Drug Resistance, Microbial; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Japan; Klebsiella pneumoniae; Molecular Epidemiology; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas putida; Serratia marcescens | 1996 |
In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.
Topics: Animals; Carbapenems; Cilastatin; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Prodrugs; Protease Inhibitors; Sepsis | 1998 |
The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen.
Topics: Bacteremia; Carbapenems; Cross Infection; Gram-Negative Bacterial Infections; Humans; Kuwait; Microbial Sensitivity Tests; Prospective Studies; Wound Infection; Xanthomonas | 1999 |
Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillins | 1999 |
Bacterial resistance, beta-lactam antibiotics and gramnegative bacteria at ICUs.
Topics: Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Contraindications; Cross Infection; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units | 1999 |
Urinary tract infection in neurogenic bladder.
Topics: Acute Disease; Anti-Infective Agents, Urinary; Carbapenems; Cephalosporins; Chronic Disease; Epididymitis; Escherichia coli Infections; Female; Fever; Gram-Negative Bacterial Infections; Humans; Klebsiella Infections; Male; Prostatitis; Pseudomonas Infections; Pyelonephritis; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Catheterization; Urinary Tract Infections | 2001 |
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999
Topics: Acinetobacter; Acinetobacter Infections; Adolescent; Adult; Aged; Anti-Bacterial Agents; Canada; Carbapenems; Child; Child, Preschool; Cross Infection; Drug Resistance, Multiple; Europe; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Latin America; Male; Microbial Sensitivity Tests; Middle Aged; Seasons; Stenotrophomonas maltophilia; United States | 2001 |
Discordant carbapenem susceptibility in Methylobacterium species and its application as a method for phenotypic identification.
Topics: Carbapenems; Drug Resistance, Microbial; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Methylobacterium; Microbial Sensitivity Tests; Phenotype; Thienamycins | 2001 |
Nosocomial bloodstream infections in a Turkish university hospital: study of Gram-negative bacilli and their sensitivity patterns.
Topics: 4-Quinolones; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Carbapenems; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, University; Humans; In Vitro Techniques; Turkey | 2001 |